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1.   Introduction  
1.1. Lung development  
The lung is a complex ramified organ, which develops through continuous 
branching during embryonic development. The elaborate interaction amongst the 
epithelium, mesenchyme, mesothelium and endothelium via an intricate signaling 
network controls the amplification, proliferation, migration and differentiation of 
many progenitor cells to populate these different compartments.  
1.1.1. Lung development: human compared to mouse 
In human and mouse, the lung arises from two germ layers during early embryonic 
development; the gut endoderm gives rise to the lung epithelium and the 
splanchnic mesoderm is the origin of the lung mesenchyme. The human lung 
consists of three lobes on the right and two lobes on the left side. In contrast, mice 
have four lobes on the right (cranial, medial, caudal and accessory lobe) and one 
on the left side. In human lungs 23 airway generations have been observed but in 
mice only 12. 
In humans, lung development begins after four weeks gestation. From the laryngo-
tracheal groove, the ventral wall of the caudal primitive foregut starts to grow and 
forms a sac-like structure. During subsequent growth of the lung, the prospective 
trachea separates from the foregut by the formation of the so-called tracheo-
esophageal septum. The most distal part of the tracheal tube divides into two buds, 
which will form the right and left primary bronchial buds. These primary buds are 
further ramified to form three secondary bronchial buds on the right and two 
secondary bronchial buds on the left side. These buds are the origin of the five 
lobes in the mature lung (Moore et al., 2002). 
In mice, at embryonic day 8 (E8), signaling molecules from the cardiac mesoderm 
like growth factors FGF1 and FGF2 among others, specify the prospective lung 
field in the primitive foregut endoderm, which expresses the transcription factor 
Nkx2.1 (or Ttf1). These NKX2.1-positive cells are the so-called pluripotent 
epithelial cells of the lung. At E9.5, similar to what has been observed in humans, 
the ventral foregut endoderm evaginates and elongates caudally, dividing into two 
buds that form the prospective trachea and the two main bronchi. The whole 
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process of lung development in humans and mice can be divided into four 
histologically distinguishable stages. The first stage is called pseudoglandular 
stage, followed by the canalicular stage and the saccular stage. Lung development 
finishes with the alveolar stage, which in humans starts prenatally but in mice 
postnatally (Figure 1). According to the developmental processes, lung 
development is split into the branching morphogenesis program from E9.5 until 
E16.5, followed by the alveolar epithelial differentiation program (Chang et al., 
2013).  
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Figure 1. Timeline and stages of lung development in mice and humans. 
Lung development starts with the specification of the lung domain in the foregut 
endoderm followed by the formation of primary lung buds. These buds will later 
give rise to the respiratory tree via the process of branching morphogenesis. The 
latter is a characteristic of the pseudoglandular stage of lung development. Most 
epithelial and mesenchymal cell types start to form during the pseudoglandular 
stage. The canalicular stage is characterized by blood capillary formation and the 
appearance of AECI/II. During the saccular stage, primitive alveoli (sac-like 
structures) start to form and this is accompanied by surfactant production and the 
expansion of capillary and lymphatic networks. The alveolar stage of lung 
development starts in utero in humans, whereas in mice, it starts postnatally (Chao 
et al., 2015). 
Wk: week; E: embryonic; PN: postnatal; NE: neuroendocrine 
 
The first stage is termed the pseudoglandular stage and takes place from 
embryonic week 4 until 17 in humans and from E9.5 until E16.5 in mice. During this 
stage the process of branching morphogenesis generates the basic tree-like 
structure of the lung including the conducting airways and the numerous terminal 
bronchioles surrounded by thick mesenchyme. At the same time, epithelial cell 
progenitors differentiate to basal, neuroendocrine, ciliated and secretory cells. The 
mesodermal lung compartment serves as progenitors for the smooth muscle, 
lymphatic, endothelial, nerve and chondrocytic cells. Importantly, most of the 
epithelial and mesenchymal cell types in the lung are formed during the late 
pseudoglandular stage (E13.5-E16.5). Accordingly, any injurious process present 
prenatally (e.g. inflammations due to chorioamnionitis) interfering with normal lung 
development at that time, could lead to disturbed formation of these two important 
compartments resulting in impaired pulmonary function postnatally.  
In the next stage, called the canalicular stage (human: week 17-26; mouse: E16.5-
E17.5), the respiratory bronchioles continue subdividing into smaller units, which 
consist of a primitive respiratory epithelium competent of gas exchange. This 
respiratory epithelium arises from differentiation of distal lung epithelial progenitors. 
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It has been shown that type I and type II alveolar epithelial cells (AEC I and II) 
emerge from a common alveolar bipotential progenitor (Treutlein et al., 2014). 
Concurrently, the mesenchyme surrounding the epithelium becomes thinner due to 
mesenchymal cell apoptosis (Kresch et al., 1998). Furthermore, another 
characteristic of this stage is the massive formation of a double-layer capillary 
network. In mice, interstitial fibroblasts containing cytoplasmic lipid droplets (so 
called lipofibroblast, LIF) emerge in the mesenchyme.  
The saccular stage of lung development occurs approximately between 26 weeks 
and 36 weeks of gestation. In contrast, in mice this stage starts prenatally at E17.5 
and ends postnatally at PN5. The main events during this stage are the formation 
of alveolar sacs, surfactant protein production and further thinning of the 
mesenchyme to facilitate gas exchange between the intraalveolar airspace and the 
capillaries located in the mesenchyme. Furthermore, expansion of the capillary and 
lymphatic networks continues. 
The last stage of lung development is termed the alveolar stage (human: ~weeks 
36 – 8 years; mouse: PN5-PN30). During this stage, the alveolar surface area 
increases massively at the expense of the mesenchyme through subdividing the 
alveolar sacs (also called primitive alveoli) into mature alveoli by secondary septa 
formation. This process is named alveolarization (or alveologenesis) and requires 
the interaction of many cell types located in the epithelium and the mesenchyme 
(Table 1).  
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 Table 1. Overview of cells relevant for alveologenesis (Chao et al., 2016). 
Name of cell Name of 
progenitor cell 
Localization of 
cell 
Function of cell for 
alveologenesis 
Interaction with other cells 
Alveolar epithelial 
cell type I  
(AEC I) 
Bipotent progenitor 
(SFTPC+, PDPN+) 
(Treutlein et al., 
2014)  
Epithelium Providing the majority of 
alveolar surface area 
AEC II (during regeneration) (Desai 
et al., 2014) 
Alveolar epithelial 
cell type II  
(AEC II) 
Bipotent progenitor 
(SFTPC+, PDPN+) 
(Treutlein et al., 
2014)  
Epithelium, close 
proximity to 
lipofibroblast 
Surfactant production, 
transdifferentiation to AEC I 
after lung injury (Desai et 
al., 2014) 
Formation and maintenance of 
Lipofibroblast via PTHRP 
(parathyroid hormone-related 
protein)/PPAR (peroxisome 
proliferator-activated receptor 
gamma) signaling pathway (Schultz 
et al., 2002; Torday & Rehan, 2002) 
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Name of cell Name of 
progenitor cell 
Localization of 
cell 
Function of cell for 
alveologenesis 
Interaction with other cells 
Alveolar 
myofibroblast  
 
 
Alveolar 
myofibroblast 
progenitor; 
PDGFR+ LIF (to 
be validated)  
(Perl & Gale, 2009)  
Mesenchyme,  
tip of growing 
secondary septa 
Deposition of Elastin in the 
apex of secondary septa 
and secondary septa 
formation  
(Noguchi et al., 1989; 
Vaccaro & Brody, 1978) 
not known  
Lipofibroblast FGF10+ 
mesenchymal cell 
(El Agha et al., 
2014; Al Alam et al., 
2015a)  
Mesenchyme, 
close proximity to 
AEC II 
Secretion of triglycerides 
and leptin for AEC II (Torday 
& Rehan, 2002) postnatal 
niche for AEC II 
(Barkauskas et al., 2013)  
AEC II (Schultz et al., 2002; Torday & 
Rehan, 2002), Epithelium (PDGFA) 
(Torday et al., 1995) 
Endothelial cell Endothelial 
progenitor cell 
(hemangioblasts) 
Subepithelial 
mesenchyme 
(SEM) 
Angio-/vasculogenesis 
important for alveologenesis 
(Thebaud et al., 2005) 
Epithelium (Lazarus et al., 2011; Del 
Moral et al., 2006) 
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Secondary septa formation starts with the deposition of elastin in primary septa 
(wall of alveolar sacs) and subsequently secondary septa emerge at the place of 
elastin and elongate towards the alveolar sac airspace to subdivide it into the 
smallest respiratory units of the lung – the mature alveoli (Figure 2). Importantly, 
concomitant with this process, primary septa, still containing a double layer of 
capillaries, become thinner and a single capillary network emerges which allows 
more efficient gas exchange (microvascular maturation). In humans the bulk of 
alveolarization takes place during the first 6 months after birth (mouse: PN5- PN15) 
(Schittny et al., 2008). The alveolar myofibroblast, localized in the mesenchyme at 
the tip of the emerging secondary septa, is the cell responsible for secondary septa 
formation. While this stage starts prenatally in humans (approximately 36 weeks of 
gestation) it starts in mice at postnatal day 5 (PN5). For this reason, the mouse 
model of bronchopulmonary dysplasia (BPD), a model of hyperoxia-induced lung 
injury in the neonatal lung of mice, is a suitable animal model to mimic lung injury 
in the premature lung corresponding to those of preterm infants. 
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Figure 2. Schematic of the secondary septa during alveologenesis. 
Most of the alveolar surface is occupied by AECI (gas exchange) whereas a minor 
surface is occupied by AECII (surfactant production). The alveolar wall consists of 
the blood capillary, lipofibroblast (LIF), resident fibroblast progenitor, alveolar 
myofibroblast (MYF) and extracellular matrix (ECM, mostly elastin). It has been 
proposed that alveolar MYF can originate from LIF but this concept needs further 
validation (Chao et al., 2015). 
 
1.1.2.  The epithelial-mesenchymal interaction during mouse embryonic 
lung development 
In mice, during the late pseudoglandular stage (E13.5) the distal lung bud consists 
of three morphologically distinguishable layers. The outer layer is called 
mesothelium, the middle layer mesenchyme and the inner layer is termed 
epithelium. Further, the mesenchyme can be subdivided into the subepithelial 
mesenchyme (SEM) and submesothelial mesenchyme (SMM). By using lineage-
tracing experiments it has been shown that the mesenchyme is populated by 
diverse progenitor cells which are positive for WNT2/GLI1/ISL1, RET, PDGFR, 
VEGFR2, PROX1 and FGF10 (Peng et al., 2013; El Agha & Bellusci, 2014; El 
Agha et al., 2014). These progenitors further differentiate into airway smooth 
muscle cells (ASMC), vascular smooth muscle cells (VSMC), resident 
mesenchymal stem cells (MSC), lipofibroblasts (LIF), endothelial cells, 
chondrocytes, nerve cells, alveolar myofibroblasts, lymphatic cells and others. It 
has been demonstrated that mesenchymal progenitor cells are not only important 
in development but also in homeostasis and regeneration after injury (Volckaert et 
al., 2011).  
In contrast to the mesenchyme, the epithelium consists of a single layer of alveolar 
epithelial cells type I (AECI) and II (AECII). Recently, it has been demonstrated that 
they arise from the same bipotential progenitor cell population (Treutlein et al., 
2014).  
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Much evidence gained by in-vitro and in-vivo experiments confirmed the important 
role of signaling molecules and proteins, which interact between epithelium and 
mesenchyme during lung development. For example, some of these signaling 
molecules that are important for the process of alveologenesis are listed in Table 2 
(see also Table 1 for cellular interactions). This elaborate epithelial-mesenchymal 
crosstalk is essential for processes of lung specification, budding and branching. 
Key ligands like Fibroblast growth factors (FGF), WNT (wingless and int), Sonic 
hedgehog (SHH) and Bone morphogenetic proteins (BMP) are shown to initiate the 
pulmonary cell fate and specify the early lung domain at the ventral foregut 
endoderm (Hines & Sun, 2014). One of the most striking findings of the importance 
of epithelial-mesenchymal interactions during lung development was provided in 
recombination studies. Isolated distal lung mesenchyme, grafted on the tracheal 
epithelium, is able to induce ectopic budding accompanied by expression of 
surfactant protein C as a marker for AECII (Shannon, 1994; Shannon et al., 1998; 
Hyatt et al., 2004).  
FGF10, one of the most important signaling molecule during embryonic lung 
development,  is expressed in the mesenchyme and signals through the FGFR2b 
receptor located on the epithelium. The genetic deletion of Fgf10 leads to lung and 
limb agenesis (Sekine et al., 1999). But induced ectopic FGFR2b signaling in the 
mesenchyme also causes disturbed development of epithelial branching (De 
Langhe et al., 2006). The authors proposed that mesenchymal FGF10 signaling 
suppresses the differentiation of alveolar myofibroblast progenitors. Furthermore, 
the blockade of FGFR2b ligands (e.g. FGF10) in the lung from E14.5 to E18.5 by 
overexpression of a soluble dominant negative receptor of Fgfr2b (Sftpc-
rtTA/+;tetOsolFgfr2b/+), which blocks all FGFR2b ligands, also leads to arrest in 
secondary septa formation and alveolar simplification (Perl & Gale, 2009). This 
data suggests that FGFR2b ligands are also essential for the formation of alveolar 
myofibroblasts. Interestingly, treatment with retinoic acid, a biologically active 
derivative of vitamin A, induced re-alveolarization with increased PDGFR-positive 
cells and decreased SMA/ACTA2-positive cells. This alveolar regeneration can 
be abolished by concurrent induction of the dominant negative Fgfr2b. These data 
suggest that re-alveolarization is dependent on FGFR2b ligands.  
Another important signaling molecule is WNT (e.g. WNT2, WNT2b among others), 
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which is expressed in the mesenchyme. By genetically deleting Wnt2/2b or -
catenin , lung agenesis due to loss of Nkx2.1 has been observed (Goss et al., 
2009; Harris-Johnson et al., 2009). These data suggest the importance of WNT 
ligands for the lung domain specification of the foregut endoderm at the beginning 
of embryonic lung development. Genetic deletion of Wnt2 in mice also leads to 
abnormal formation of airway smooth muscle cells (ASMC) (Goss et al., 2011). The 
conditional deletion of -catenin in the distal epithelium (Spc-rtTA;tet(O)Cre)  in 
mice results in the inhibition of distal airway formation (Mucenski et al., 2003). This 
phenotype could be rescued by a gain of function approach for -catenin 
(Mucenski et al., 2005).  
BMP4 (Bone morphogenetic protein 4), SHH (Sonic hedgehog) and SPRY2 
(Sprouty homolog 2) are inhibitors of FGF10. BMP4 is expressed in the endoderm, 
the mesenchyme and also in the distal epithelial buds. In vitro treatment with 
exogenous recombinant BMP4 leads to inhibition of FGF10-induced bud 
outgrowth. In comparison, SHH and SPRY2 are expressed in the epithelium of the 
distal buds. SHH, a secreted growth factor, signals in a paracrine fashion through 
the receptor Patched (PTC), which is located in the mesenchyme. In vitro 
experiments with lung explants demonstrated that SHH induce mesenchymal cell 
proliferation and differentiation (El Agha & Bellusci, 2014; Minowada et al., 1999). 
In contrast, SPRY2 inhibits the intracellular receptor tyrosine kinase signaling 
(Mailleux et al., 2001; Tefft et al., 2002; Bellusci et al., 1997a) and causes 
decreased epithelial branching. 
Additional evidence for the importance of epithelial-mesenchymal interaction has 
been shown in AECII and lipofibroblast. The lipofibroblast (LIF) is a lipid-containing 
interstitial cell located in the mesenchyme in close proximity to AEC II (Figure 2). 
LIF are involved in the trafficking of lipids to the AECII for surfactant production 
(Torday et al., 1995; Tordet et al., 1981). Apart from triglycerides, LIF also secrete 
leptin and retinoic acid, both important for surfactant production and alveolar 
septation (Torday & Rehan, 2002; Simon & Mariani, 2007). On the other hand, 
AECII secrete parathyroid hormone-related protein (PTHRP) to signal through 
PTHRP receptors expressed on LIF, inducing expression of adipose differentiation-
related protein (Adrp) via the peroxisome proliferator-activated receptor gamma 
(PPAR) pathway (Figure 4). The current consensus is that this signaling pathway 
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is essential for the maintenance of the LIF phenotype as well as for regulation of 
surfactant production (Schultz et al., 2002; Torday & Rehan, 2002; Rehan & 
Torday, 2012; Rubin et al., 2004). 
 
1.2.  Bronchopulmonary dysplasia  
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of prematurely born 
infants and remains a leading cause of morbidity and mortality in newborns. The 
main histological characteristic is alveolar simplification. Until now there is no 
curative therapy for BPD. According to data from the Neonatal Research Network 
in the United States and the new severity-based definition of BPD 68% of 
premature infants born at the gestational age ≤ 28 weeks or at a birth weight lower 
than 1500g develop BPD (Stoll et al., 2010). The lower the gestational age and the 
birth weight, the higher is the risk to develop BPD (Bhandari & Bhandari, 2009). 
Long-term morbidity, such as susceptibility to pulmonary infection, asthma and 
neurodevelopmental impairment in child- and adulthood affect life quality and 
represent a considerable burden for the patients and health care systems.   
The pathogenesis is known to be multifactorial (Figure 3), but the underlying 
molecular and cellular mechanisms are still poorly understood. In the following 
sections, more details regarding the pathogenesis, both from a clinical and from a 
basic scientific point of view, will be provided. 
1.2.1.  Pathogenesis of BPD from a clinical point of view  
As mentioned above, the risk of BPD correlates inversely with the gestational age 
and the birth weight. This fact is associated with the need of mechanical ventilation 
and high oxygen delivery due to insufficient gas exchange in the immature lung 
postnatally. The barotrauma and oxygen toxicity associated with mechanical 
ventilation lead to inflammation contributing to damages of the lung structure. Apart 
from these major risk factors for BPD, pre- (e.g. chorioamnionitis) and postnatal 
infections (e.g. sepsis) are known to be further major factors, which cause lung 
injury (Figure 3) (Baraldi & Filippone, 2007). Pulmonary inflammatory responses 
due to bio- and barotrauma are characterized by an imbalance of pro-inflammatory 
cytokines and growth factors followed by the influx of inflammatory cells into the 
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lung (Shahzad et al., 2016). Using tracheal aspirates of mechanical ventilated 
preterm infants, several studies confirmed that high levels of pro-inflammatory 
cytokines like IL-1, IL-6, IL-8 and TNF- are associated with the later 
development of BPD (Todd et al., 1998; Speer, 2006). In the past two decades, 
advances in the treatment and management of preterm infants postnatally have 
been made. Among others, these advances include the prenatal use of 
corticosteroids (Roberts & Dalziel, 2006), the avoidance of invasive mechanical 
ventilation and the use of exogenous surfactant. Concurrent with these changes in 
treatment, the histological findings in autopsy specimens of infants who died from 
BPD have been changed. Main histological characteristics in the so-called “old” 
BPD (before the invention of exogenous surfactant) are interstitial fibrosis and 
squamous metaplasia of the airways. Lungs from “new” BPD during the post-
surfactant era display mainly alveolar simplification and an immature 
microvasculature. According to these findings the “new” BPD is considered as a 
lung disease, which affects preterm infants born in the canalicular/saccular stage of 
lung development (e.g. 23 – 28 weeks of gestation), when lung development is 
interrupted by postnatal lung injury leading to the growth arrest of the lung with 
impaired secondary septation and decreased alveolar surface area. Using animal 
models, some of the major proteins that are involved in this process of 
alveologenesis and that are altered in patients with BPD have been described 
(Table 2). Further postnatal lung development in the alveolar stage is not able to 
catch up and to compensate this growth deficit leading to persistent limitations in 
lung function. This growth arrest also affects the development of the pulmonary 
vessels resulting in up to 25% of pulmonary hypertension – a severe clinical 
complication - in preterm infants with BPD (Rossor & Greenough, 2015). Finally, 
since not all of the preterm infants develop BPD, it has been proposed - based on 
results from genome-wide association studies - that polymorphisms (SNPs) in 
MMP16 and SPOCK2 might be associated with BPD (Hadchouel et al., 2011).  
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Figure 3. Schematic of the multifactorial pathogenesis of bronchopulmonary 
dysplasia (BPD). 
Lungs of premature infants are often exposed to both pre- and/or postnatal 
injurious events (e.g. pre-/ postnatal infections, ventilator-induced lung injury, 
oxidative stress) leading to development of BPD. In the earlier time, the “old” BPD 
occured in premature infants born during the alveolar stage with respiratory 
distress syndrome who received aggressive mechanical ventilation and high 
concentrations of inspired oxygen. Nowadays, due to advances in prevention and 
treatment of respiratory distress syndrome (e.g. prenatal steroids, postnatal 
surfactant application, avoidance of invasive mechanical ventilation), BPD is 
considered as a developmental arrest or delay of the lung (“new” BPD) of 
premature infants, mainly born during the canalicular or saccular stages of lung 
development (adapted from Baraldi & Filippone, 2007).  
 
1.2.2.  Pathogenesis of BPD from a basic scientific point of view  
As stated previously, the mechanisms responsible for alveolar simplification in BPD 
remain elusive. However, lung specimens from premature infants from pre- and 
post-surfactant era who died from BPD consistently showed abnormalities in the 
mesenchyme (interstitial fibrosis and dysmorphic microvasculature) with increased 
total collagen content (Husain et al., 1998; Thibeault et al., 2000; Thibeault et al., 
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2003). Similar findings in plenty of animal models (rat, mice, baboon) mimicking the 
BPD conditions (oxygen delivery, mechanical ventilation, exogenous surfactant) 
support the hypothesis that the mesenchyme plays a pivotal role in disease 
pathogenesis (Warner et al., 1998; Dauger et al., 2003; Auten et al., 2009; Velten 
et al., 2010; Coalson et al., 1999) and reinforce the opinion that alveologenesis 
depends on a normally developed mesenchyme. Some of the most important 
proteins that are responsible for alveologenesis but that has been shown to be 
altered in humans with BPD will be described in the next section and listed in Table 
2. 
As described above, one of the major causes of BPD is believed to be 
inflammation. In line with what can be taken from studies with human samples (e.g. 
tracheal aspirates), increasing evidence gained in animal experiments support this 
hypothesis (Prince et al., 2005; Blackwell et al., 2011; Benjamin et al., 2010; 
Carver et al., 2013; Benjamin et al., 2007). For instance, it has been shown that 
lipopolysaccharides (LPS from Escherichia coli) inhibit branching morphogenesis in 
vitro (Prince et al., 2005). Blackwell and colleagues also observed the inhibition of 
airway branching in lung explants once incubated with activated resident 
macrophages. The proposed mechanism is that LPS activates nuclear factor 
kappa beta (NF-B), which is then accompanied by increased activation of 
interleukin-1beta (IL-1) and tumor necrosis factor- (TNF-) in resident 
macrophages (Blackwell et al., 2011). This effect caused by macrophage-mediated 
inflammation could be antagonized by depletion of macrophages in the lung. This 
inhibitory effect of inflammatory signals is linked with FGF10 – a key growth factor 
during lung development. In vitro experiments demonstrated that Fgf10 expression 
is decreased in LPS-treated lung explants and primary fetal lung mesenchymal 
cells from saccular stage through activation of Toll-like receptors 2 and 4 (TLR2/4). 
Further, immunostaining showed a significantly lower quantity of FGF10-positive 
cells in lung tissues of premature infants who died from BPD (Benjamin et al., 
2007). In line with this observation, a prospective study evaluating FGF10 levels in 
cord blood of 269 preterm infants found that low cord blood FGF10 levels may 
predict the subsequent development and severity of BPD (Mohamed & Aseeri, 
2014). 
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Furthermore, it has been shown recently that mRNA and protein expression of 
PDGFR and PDGFR in mesenchymal stromal cells (MSC) isolated from tracheal 
aspirates of premature neonates with BPD are decreased. Consistent with these 
findings, lungs of infants dying from BPD display less PDGFR-positive cells in the 
alveolar septa. These data have been confirmed in animal studies using a BPD 
mouse model (75% oxygen for 14 days) (Popova et al., 2014). Most recently, using 
a novel three-dimensional human model of fibroblast activation associated with 
exposure to alternating hypoxia and hyperoxia, Sucre and colleagues identified the 
Notch pathway as a key driver of fibroblast activation and proliferation in response 
to changes in oxygen thereby contributing to BPD pathogenesis (Sucre et al., 
2016). 
As previously mentioned, the alveologenesis phase leads to a dramatic increase in 
alveolar surface, which is essential for gas exchange. The current consensus is 
that this process is interrupted by exogenous deleterious factors leading to 
simplification of alveoli in BPD. Many studies confirmed that the alveolar 
myofibroblast (MYF), located in the mesenchyme, is the unique cell type 
responsible for secondary septa formation. During alveologenesis, the alveolar 
myofibroblast is characterized by expression of alpha-smooth-muscle-actin (SMA 
or ACTA2) compared to other mesenchymal fibroblast population. By deposition of 
elastin and collagen, the alveolar myofibroblast initiates the process of secondary 
septation (Noguchi et al., 1989; Vaccaro & Brody, 1978). Both elastin and alveolar 
myofibroblast have been shown to be critical for secondary septa formation 
(Vaccaro & Brody, 1978; Dickie et al., 2008). Expression of tropoelastin starts in 
the pseudoglandular stage of lung development and reaches the highest level 
during the alveolar stage (Mariani et al., 1997; Willet et al., 1999). The strongest 
evidence so far showing the importance of elastin for secondary septa formation 
came from the elastin-knock-out mice that reveal a complete failure of 
alveologenesis leading to an emphysematous-like phenotype (Wendel et al., 2000; 
Shifren et al., 2007). Interestingly, both hyperoxia and mechanical ventilation lead 
to increased expression of elastin (Bruce et al., 1993; Albertine et al., 1999; 
Nakamura et al., 2000). Fgfr3 and Fgfr4 have been shown to direct alveologenesis 
in the murine lung by controlling elastogenesis (Weinstein et al., 1998). By using 
mice homozygous for Pdgfa-null allele, Boström and colleagues demonstrated 
failed alveolar formation due to loss of alveolar myofibroblasts and consequent loss 
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of elastin fibers (Bostrom et al., 1996; Lindahl et al., 1997). Likewise, blocking 
antibody against PDGR in newborn mice (PN1-PN7) led to aberrant elastin fiber 
deposition and impaired alveolar septation resulting in long-term failure in 
alveologenesis that lasted into adulthood. PDGFA is expressed in the epithelium 
and targets its receptor (PDGFR) on mesenchymal cells such as alveolar 
myofibroblast and lipofibroblast. Given the many mesenchymal targets of PDGFA, 
it is not clear whether the impact of Pdgfa or Pdgfr deletion on myofibroblast 
formation is due to a direct effect of PDGFA on alveolar myofibroblasts (and or 
alveolar myofibroblast progenitors) or whether it occurs indirectly via PDGFA action 
on other targets (ASMCs and LIF). Gain and loss of function for PDGFA/PDGFR 
signaling using cell autonomous-based approaches in specific lineages should be 
carried out in the future to sort out these issues. During a pathological process, 
VEGFA has been found down-regulated in preterm infants with BPD (Bhatt et al., 
2001; Lassus et al., 1999; Lassus et al., 2001). Furthermore, Thebaud and 
colleagues demonstrated that Vegf and Vegfr2 are decreased in the hyperoxia 
model of BPD in newborn rats and that adenoviral administration of VEGF 
improved alveolar architecture and promoted capillary formation (Thebaud et al., 
2005; Kunig et al., 2005). Although the trophic and angiogenic potential of VEGF 
on the lung vasculature is known, the aforementioned study and the studies from 
other groups suggest that vascular growth serves as a driving force for alveolar 
growth and maturation, leading to improvement of lung structure and promoting 
secondary septa formation. A recent report revealed the association of a VEGF 
polymorphism with BPD in Japanese preterm newborns (Fujioka et al., 2014). 
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 Table 2. Overview of proteins that are known to be involved in alveologenesis (Chao et al., 2015). 
Protein 
name 
Origin Localization/
Targets 
Function in 
alveologenesis 
Alterations in 
humans with BPD 
Alterations in 
animal model of 
BPD 
Effect of genetic 
modulation in the   
animal model 
ELASTIN Alveolar 
myofibroblast 
Tip of 
growing 
secondary 
septa 
secondary septa 
formation (tips) 
Increased and 
disorganized in 
saccular walls 
(Thibeault et al., 
2000; Thibeault et 
al., 2003) 
Decreased in 
hyperoxia (Bruce et 
al., 1989) 
KO: inhibited 
alveolarization (Wendel 
et al., 2000) 
PDGFA Epithelial 
cells, 
macrophages 
Pdgfr-
expressing 
cells (ASMC, 
alv. MYF, 
LIF) 
Chemotactic 
attractant for 
fibroblasts 
(Prodhan & 
Kinane, 2002) 
Not known Delayed in hyperoxia 
(Buch et al., 2000) 
 
KO: inhibited 
alveolarization (Bostrom 
et al., 1996; Lindahl et al., 
1997) 
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Protein 
name 
Origin Localization/
Targets 
Function in 
alveologenesis 
Alterations in 
humans with BPD 
Alterations in 
animal model of 
BPD 
Effect of genetic 
modulation in the   
animal model 
FGF10  Mesenchymal 
cells located 
in SMM 
Distal 
epithelial 
cells 
expressing 
FGFR2b 
Under 
investigation 
Decreased 
(Benjamin et al., 
2007) 
Decreased in LPS-
model (Benjamin et 
al., 2010) 
KO: lung agenesis 
Partial deficiency: 
delayed/ disturbed lung 
branching (Ramasamy et 
al., 2007) 
TGF-/ 
TGF-1 
Epithelial 
cells 
Epithelial and 
mesenchymal 
cells 
Modulation of 
cell survival, 
differentiation 
and ECM ( 
elastin) 
deposition 
(McGowan & 
McNamer, 
1990; McGowan 
et al., 1997) 
Increased in 
tracheal aspirate 
(Kotecha et al., 
1996) 
Increased in 
hyperoxia (Nakanishi 
et al., 2007; 
Alejandre-Alcazar et 
al., 2007) 
Overexpression: 
inhibition of branching 
morphogenesis and 
alveolarization (Gauldie 
et al., 2003) 
Inhibition: attenuated 
hyperoxia-induced 
hypoalveolarization 
(Nakanishi et al., 2007) 
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Protein 
name 
Origin Localization/
Targets 
Function in 
alveologenesis 
Alterations in 
humans with BPD 
Alterations in 
animal model of 
BPD 
Effect of genetic 
modulation in the   
animal model 
VEGF Epithelial 
(during 
embryonic 
development 
also in 
mesenchymal 
cells) 
Endothelial 
cells 
(VEGFR1/2)  
Stimulation of 
endothelial cells 
for angio-/ 
vasculogenesis 
(essential for 
alveolarization) 
Decreased (Bhatt 
et al., 2001; 
Lassus et al., 
2001) 
Decreased in 
hyperoxia (DeLisser 
et al., 2006; Lassus 
et al., 1999) 
Inhibition: 
hypoalveolarization (Le 
Cras et al., 2002; 
McGrath-Morrow et al., 
2005)  
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Hyperoxia injury, one of the major risk factor in BPD pathogenesis, is thought to 
disrupt critical signaling pathways that direct lung development, including 
branching and septation (Warner et al., 1998). Many signaling pathways critical to 
these processes have been described (Roth-Kleiner & Post, 2005), notable among 
them, signaling by the fibroblast growth factor 10 (FGF10) and transforming growth 
factor (TGF)- superfamily (Jankov & Keith Tanswell, 2004). Several studies have 
confirmed the role of TGF-1 in inducing epithelial-mesenchymal transition (EMT) 
of alveolar epithelial cells (AEC) to myofibroblast-like cells. This process is 
accompanied by the deposition of extracellular matrix (ECM) leading to the 
formation of fibrotic areas in the lung and destruction of alveoli (Kim et al., 2006; 
Willis et al., 2005; Phan, 2002). Transforming growth factor (TGF)- signaling can 
negatively regulate the branching (Roth-Kleiner & Post, 2005; Jankov & Keith 
Tanswell, 2004) and septation (Gauldie et al., 2003; Vicencio et al., 2004) phases 
of lung development. In case of the latter, adenoviral-mediated transfer of Tgf-1 to 
the neonatal rat lung or overexpression of Tgf-1 between postnatal days P7 and 
P14 in the mouse both induced histological changes analogous to those seen in 
BPD. Furthermore, Smad3 knockout mice exhibited retarded alveolarization 
between days P7 and P28 (Chen et al., 2005), suggesting that Tgf- also acts as a 
positive regulator of septation. This apparent paradox indicates that TGF- 
signaling plays a critical and finely tuned role in alveolarization. Consistent with 
these data, Smad3 deficiency in adult mice caused air space enlargement and 
centrilobar emphysema in late life (Bonniaud et al., 2004), suggesting a key role for 
TGF- signaling in both the formation of alveoli and the maintenance of alveolar 
structure. However, despite a clear role in both normal and aberrant lung 
alveolarization (Morty et al., 2009), little is known about how TGF- signaling 
regulates secondary septation and the generation of the alveolar gas exchange 
units. It has been hypothesized that the interplay between FGF signaling and TGF-
 signaling plays a pivotal role in orchestrating the balance of 
amplification/differentiation of the epithelial alveolar lineage during embryonic lung 
development as well as homeostasis/regeneration in postnatal lung injury. 
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Figure 4. Model for the interplay of FGF10 and TGF- signaling in epithelial 
(AECII) - mesenchymal (LIF/MSC) crosstalk during embryonic lung  
development and disease.  
FGF10 secreted by lipofibroblasts (LIF) (among others) acting on AECII via 
FGFR2b signaling (AKT/pERK). TGF- expressed by epithelial cells is acting either 
in an autocrine fashion to finely tune the balance with FGFR2b signaling or on the 
mesenchym. Further, LIF provides AECII with triglycerides (essential for surfactant 
production) and interact through leptin signaling molecules. In contrast, AECII 
signals via PTHRP towards LIF (still controversial). It remains to be proven whether 
FGF10 secreted by AECII acts in an autocrine manner to control survival, renewal 
and proliferation (Chao, unpublished). 
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1.3.  FGF10 in lung development and disease  
1.3.1.  What do we know from experimental studies? 
FGF10 is one of the most important signaling molecule during lung development. 
This has been shown by genetic deletion of Fgf10 resulting in lung agenesis 
(Sekine et al., 1999; Bellusci et al., 1997a; Bellusci et al., 1997b). FGF10 belongs 
to a family of fibroblast growth factor which consists of 22 members subdivided in 
seven subfamilies (Itoh & Ornitz, 2011). Fibroblast growth factors act in an 
endocrine, paracrine or intracrine manner through seven receptors (FGFR 1b, 1c, 
2b, 2c, 3b, 3c and 4). These receptors are encoded by four genes called Fgfr1, 
Fgfr2, Fgfr3 and Fgfr4. Due to alternative splicing seven receptors with different 
ligand-binding specificity are expressed. Each receptor consists of three domains: 
an extracellular ligand-binding domain with three immunoglobulin-like loops (D I, D 
II, D III), a transmembrane domain and an intracellular tyrosine kinase domain. 
At E12.5, during the early pseudoglandular stage of embryonic mouse lung 
development, FGF9 and FGF10 are essential for the branching morphogenesis as 
well as the differentiation of the epithelium and mesenchyme. FGF9 is expressed 
in the mesothelium and the epithelium and acts through FGFR2c and FGFR1c 
located on mesenchymal cells to maintain Fgf10 expression as well as 
mesenchymal progenitor cells in a proliferative and undifferentiated status (del 
Moral et al., 2006). FGF10 is a diffusible key molecule controlling branching 
morphogenesis during early lung development in mice (Bellusci et al., 1997a; 
Bellusci et al., 1997b) but the exact mechanism of action remains unclear. Among 
other Fgfs, Fgf10 is the only gene, which is expressed during the early 
pseudoglandular stage. FGF10 is secreted by mesenchymal cells located in close 
proximity to the mesothelium at the distal lung buds. FGF10 acts in a paracrine 
manner and binds mainly to fibroblast growth factor receptor 2-IIIb (FGFR2b) 
expressed on epithelial cells. Via chemotaxis FGF10 induces outgrowth of the 
distal epithelium. Several studies using transgenic mouse lines with a dysfunction 
in FGF10/FGFR2b signaling showed an abnormal branching morphogenesis, 
thereby confirming the importance of this pathway. Genetic deletion of Fgf10 or 
Fgfr2b in mice led to a similar phenotype. The mutant pups die shortly after birth 
due to lung agenesis and multiple defects in other organs such as salivary gland, 
limb, inner ear, teeth, skin, pancreas, kidney, thyroid, pituitary gland, mammary 
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gland (Arman et al., 1999; De Moerlooze et al., 2000; Peters et al., 1994; Sekine et 
al., 1999; Mailleux et al., 2002). 
Lu and colleagues treated mesenchyme-free epithelium with recombinant human 
FGF10 to identify epithelial-specific gene expressions during bud morphogenesis 
(Lu et al., 2005). Microarray analysis revealed a panel of transcriptional Fgf10 
targets, which are associated with cell rearrangement, migration, inflammatory 
processes, lipid metabolism, cell cycle and tumor invasion. Interestingly, the 
authors did not observe a remarkable induction of genes responsible for 
proliferation. Fgf10 also controls the amplification of distal epithelial cell progenitors 
and the formation of multiple mesenchymal lineages during lung development. 
Hypomorphic Fgf10lacZ/- pups that have only approximately 20% Fgf10 expression 
level compared to wild type (WT) display lung defects at birth with decreased 
branching, thickened primary septa and vascular abnormalities with intrapulmonary 
hemorrhages. They died within 24-48 hours after birth. Furthermore, Fgf10 
deficiency led to decrease in Nkx2.1- and Sftpb-expressing cells, which suggests 
that adequate Fgf10 expression level is critical for the amplification of epithelial 
progenitors. Apart from the epithelium, a constitutive decrease in Fgf10 expression 
affects not only the epithelium but also diminished PECAM and SMA-positive 
cells in mesenchymal cell lineages (Ramasamy et al., 2007).  
1.3.2.   What is known in humans? 
Humans with heterozygous mutations in the FGF10 or FGFR2B gene are suffering 
from ALSG (aplasia of lacrimal and salivary glands) and LADD (lacrimo-auriculo-
dento-digital) syndroms, respectively (Entesarian et al., 2005; Rohmann et al., 
2006; Milunsky et al., 2006). Compared to infants with ALSG or LADD who do not 
show obvious lung defects, adult patients with haploinsufficiency of FGF10 
developed a significant decrease in lung function parameters (IVC, FEV1 and 
FEV1/IVC ratio) compared to non-carrier siblings which is similar in patients with 
chronic obstructive pulmonary disease (COPD) (Klar et al., 2011). Recently, it was 
shown in 220 COPD patients that polymorphisms in FGF10 maybe be associated 
with susceptibility to COPD and severity of COPD (Ren et al., 2013). Based on our 
recent data gained from Fgf10 heterozygous (Fgf10+/-) mice we hypothesize that 
these patients acquired quantitative and qualitative congenital defects of the AECI 
and AECII cells due to Fgf10 deficiency (Chao et al., 2017). As mentioned above, 
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FGF10-positive cells are diminished in lung autopsy tissues from infants died from 
BPD (Benjamin et al., 2007). The underlying mechanism is unclear. 
Apart from FGF10, mutations of other FGF genes are also associated with 
diseases. For instance, homozygous mutation of FGF3 leading to impaired 
secretion of FGF3 is described to cause deafness due to complete labyrinthine 
aplasia (Michel aplasia), microtia, and microdontia (LAMM syndrome) (Tekin et al., 
2007). Mutations of FGF23 lead to polypeptides less sensitive to protease 
cleavage compared to WT resulting in excessive loss of phosphate in the urine. 
This hereditary disease is called “autosomal dominant hypophosphatemic rickets” 
(ADHR) (White et al., 2001). 
Objectives 
 
25 
2.   Objectives  
Inflammation-induced Fibroblast growth factor 10 (FGF10) protein deficiency is 
associated with bronchopulmonary dysplasia (BPD) (Prince et al., 2005; Blackwell 
et al., 2011; Benjamin et al., 2010; Carver et al., 2013; Benjamin et al., 2007), a 
chronic lung disease of prematurely born infants characterized by arrested alveolar 
development. Until today, there is no experimental evidence for a direct role of 
FGF10 in BPD. For this reason, we used two mouse lines with constitutive Fgf10 
deficiency (Fgf10+/- and Fgf10Lacz/-) to investigate the effect on lung development 
pre- and postnatally as well as in a BPD mouse model (hyperoxia-induced lung 
injury). Furthermore, we also used an inducible loss of function of FGF10/FGFR2b 
signaling (Rosa26rtTA/+;Tg(tet(o)sFgfr2b)/+) to study the role of this signaling 
pathway pre- and postnatally in normoxia and during hyperoxia lung injury 
postnatally. 
With the experiments performed in this study we aim to answer the following five 
main questions: 
1) Does constitutive Fgf10 deficiency affect embryonic lung development?  
2) What is the impact of constitutive Fgf10 deficiency on the cellular and 
molecular level of the developing lung? 
3) What is the impact of constitutive Fgf10 deficiency on hyperoxia lung injury 
in the newborn (BPD mouse model)? 
4) Does blockade of FGF10/FGFR2b signaling affect embryonic and postnatal 
lung development? 
5) Is FGF10/FGFR2b signaling relevant during postnatal hyperoxia lung injury? 
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3.   Materials and Methods  
3.1.  Study approval 
Animal experiments were approved by the Federal Authorities for Animal Research 
of the Regierungspräsidium Giessen, Hessen, Germany, protocol GI 20/10, 
no.105/2011. The experiments shown in Figures 14 and 15 were carried out under 
the protocol no. 31-08 at Children´s Hospital Los Angeles, in accordance with the 
National Institutes of Health Guidelines for the Use of Laboratory Animals.  
3.2.  Generation and genotyping of mice   
3.2.1.  Generation of Fgf10+/-, Fgf10Lacz/- and Rosa26rtTA/+;Tg(tet(o)sFgfr2b)/+ 
Fgf10+/- mice were generated by crossing Fgf10flox/flox mice (Fgf10tm1.2Sms/J, 
Jackson Lab stock 023729) with CMV-Cre mice (B6.C-Tg(CMV-cre)1Cgn/J, 
Jackson Lab stock 006054). The resulting Fgf10+/- mice (Fgf10tm1.1Sms/J) were 
crossed for at least five generations with C57BL/6 mice. Fgf10+/- and Fgf10+/+ 
embryonic and postnatal mice were used (both males and females). The Fgf10Lacz/- 
embryos were previously generated (Danopoulos et al., 2013) by crossing the 
Fgf10(Lacz/+) (Fgf10Tg(Myl3-lacZ)24Buck  obtained from Dr. Robert Kelly, Marseille, 
France and maintained on the C57BL/6 background for at least 5 generations) with 
the Fgf10+/- mice previously described. The Rosa26rtTA/+;Tg(tet(o)sFgfr2b)/+ mice 
(Gt(ROSA)26SorTm1.1(rtTA,EGFP)Nagy Tg(tet0-sFgfr2b)1Jaw/CHC) were generated by 
crossing Rosa26rtTA/+ (Gt(ROSA)26SorTm1.1(rtTA,EGFP)Nagy) with Tg(tet(o)sFgfr2b)/+ 
mice (Tg(tet0-sFgfr2b))1Jaw/CHC, obtained from Dr. Jeffrey Whitsett, Cincinnatti, 
USA). The mice were kept on the CD1 background for at least 5 generations. Both 
male and female mice were used for the study. C57BL/6 males and females were 
used to generate wild type pups. 
3.2.2.  Genotyping of Fgf10+/-, Fgf10Lacz/- and Rosa26rtTA/+;Tg(tet(o) 
sFgfr2b)/+ 
Tissues from the distal tip of the tails were digested in 200ul Viagen including 1ul 
proteinase K in 55°C on a shaker overnight, then reaction was stopped in 85°C for 
30min. Genotyping were done by PCR. For protocol and primer sequences please 
see Table 3. Genotyping were mainly done by a technician. 
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 Table 3. Primer sequences and protocols for genotyping. 
Mouse line Primer sequence  PCR protocol 
Step Temp. (°C) Time 
Fgf10+/-  1) GCA GAG ATT GCA AAG GAA GC 
2) GTC TTT TTG ACT GAA ACC TCA C 
3) ATC CTT GGG AGG CAG GAT AAC C 
 
1 94 3min 
2 94 30sec 
3 60 30sec 
4 (repeat Step 2-4 39 
times total) 
72 1min 
5 72 10min 
6 4 hold 
Fgf10Lacz/-  1) LacZ: TTC ACT GGC CGT CGT TTT ACA ACG TCG TGA  
2) LacZ: ATG TGA GCG AGT AAC AAC CCG TCG GAT TCT  
3) Mlc1v: CGA GTG GAG CAT GTA CTT CCG TGT CCT GAA 
4) Mlc1v: TCC CTA CCC AGT CAC AGT CAC AGC TGC ATA 
1 94 1/2min 
2 94 30sec 
3 59 30sec 
4 (repeat Step 2-4 31 
times total) 
72 1min 
5 72 5min 
6 4 Hold 
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Mouse line Primer sequence  PCR protocol 
Step Temp. (°C) Time 
Rosa26rtTA/+ 
 
1) GAG TTC TCT GCT GCC TCC TG 
2) CGA GGC GGA TAC AAG CAA TA 
3) AAG ACC GCG AAG AGT TTG TC 
1 94 3min 
2 63 1min 
3 72 1,5min 
4 (repeat Step 2-4 35 
times total) 
93 1min 
5 72 5min 
6 4 hold 
Tg(tet(o)sFgfr
2b)/+ 
1) GAA GGA GAT CAC GGC TTC C 
2) AGA CAG ATG ATA CTT CTG GGA CTG T 
1 95 2min 
2 95 5sec 
3 65 5sec 
4 (repeat Step 2-4 35 
times total) 
72 20sec 
5 72 2min 
6 4 hold 
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3.2.3.  Gel electrophoresis 
PCR products were analyzed using a 1,5 % agarose gel containing TAE buffer with 
Sybrsafe (50 l Sybrsafe + 500ml 1x TAE buffer). 10 l of PCR samples were 
loaded with 2 l loading dye (Biorad Nucleic Acid Sample loading buffer, 5x), then 
gel was run with 120V for 30-45 min. A molecular ladder (QX Size Marker, 100bp-
2,5kb, Qiagen, Germany) was used to detect the expected band sizes (Table 4). 
Table 4. Expected band size of genotyping products. 
Mouse line Expected band 
size for WT 
Expected band size for 
mutant 
Fgf10+/-  174bp 500bp 
Fgf10Lacz/-  500bp 370bp 
Rosa26rtTA/+;Tg(tet(o)sFgfr2b)/+ Rosa26rtTA: 
322bp 
Rosa26rtTA: 215bp  
solFgfr2b: 110bp 
 
3.3.  Mice and doxycycline administration  
In order to induce the expression of soluble Fgfr2b in 
Rosa26rtTA/+;Tg(tet(o)sFgfr2b)/+, doxycycline food (625 mg doxycycline/kg) was 
given to pregnant females from E18.5 after plugging until postnatal day 3 of the 
pups. For the experiments shown in Figure 14 and Figure 15 one single 
intraperitoneal injection of doxycycline (0.0015 mg per gram body weight) was 
given to pregnant females. Then, doxycycline food (625 mg doxycycline/kg) was 
given to pregnant females until E18.5. 
3.4.  BPD mouse model: hyperoxia-induced lung injury   
Newborn pups were subjected to HOX (85% O2) injury from P0-P8 in a chamber 
(Proox Model 110, Biospherix, USA). To minimize oxygen toxicity and bias, nursing 
dams were rotated every 24 h between NOX and HOX. Pups and dams received 
food and water ad libitum. 
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3.5.  Lung perfusion and isolation  
After the mice were sacrificed the lung was flushed from the right ventricle to 
remove blood cells, then perfused through the trachea with a pressure of 20 cm 
H2O with 5 ml 4% PFA. The trachea was tied off with a string, and the lung was 
removed and placed in 4% PFA for max. 24 h at 4°C. Lungs were then 
progressively dehydrated (30%, 50%, 70%, 99% ethanol, each 3 h), incubated in 
xylole, then in paraffine overnight and finally embedded with a Leica embedding 
machine (EG 1150C). Paraffin blocks were kept cold and 5 μm sections were 
cutted. 
3.6.  RNA extraction and quantitative real-time RT-PCR  
The cranial lobes were removed, placed in QIAzol lysis reagent (Qiagen GmbH, 
Hilden, Germany), homogenized in GentleMACs and frozen in liquid nitrogen for 
RNA extraction. RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to manufacturer´s instructions.  
RNA was reverse-transcribed (QuantiTect Reverse Transcription Kit, Qiagen, 
Hilden, Germany). cDNA was diluted to a concentration of 5 ng/μL. Primers were 
designed using Roche Applied Sciences online Assay Design Tool. All primers 
were designed to span introns and blasted using NCBI software for specificity. 
Sybr Green Master Mix (invitrogen, Germany) was use for RT-PCR with a Roche 
LightCycler 480 machine. Samples were run in triplicates using Hprt as a reference 
gene. Mouse primers are listed below (Table 5). 
Table 5. Primer sequences (forward/reverse) for qPCR. 
Gene Forward sequence (5'-3') Reverse sequence (5'-3') 
Fgf1 CCGAAGGGCTTTTATACGG TCTTGGAGGTGTAAGTGTTATAATGG 
Fgf3 GATTACTGCGGTGGAAGTGG CCGTTCCACAAACTCACACTC 
Fgf7 ACTATCTGCTTATAAAATGGCTGCT GTGGGGCTTGATCATCTGAC 
Fgf10 CGGGACCAAGAATGAAGACT GCAACAACTCCGATTTCCAC 
Hprt CCTAAGATGAGCGCAAGTTGAA CCACAGGACTAGAACACCTGCTAA 
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3.7. -smooth muscle actin/ von-Willebrand-factor (vWF) double 
staining  
3 μm paraffine sections were deparaffinized, endogenous peroxidase was removed 
by incubation with 3% H2O2-methanol solution for 20 min, then washed with aqua 
dest. and PBS each 2 x 5 min. For antigen retrieval, sections were trypsinized for 
10 min at 37°C, then washed with PBS (4 x 5 min) and immersed in blocking buffer 
(10% BSA) for a further 20 min. After washing with PBS (4x 5 min), sections were 
blocked with Rodent Block M (Biocare Medical MM HRP-Polymer Kit, Cat. No. 1-
800-799-9499) for 30 min, washed with PBS and incubated with primary antibody 
(alpha-actin 1:800 diluted, 30 min) and HRP polymer (20 min) before immersed in 
substrate solutions (Vip substrat Kit, vector, 30 sec – 4 min). Slides were monitored 
under the microscope for staining progression and washed with tap water for 5 
min. Before staining for vWF, sections were immersed in blocking buffer (10% 
BSA) for 15 min, washed with PBS, blocked with serum (ImmPRESS Kit Anti-rabbit 
Ig), then sections were incubated with vWF antibody (1:1200 diluted) at 37°C for 30 
min and washed again. After incubation with secondary antibody (Anti-rabbit Ig 
peroxidase, ImmPRESS reagent), sections were stained with DAB substrate Kit 
(SK-4100, vector) and staining progression was observed under the microscope. 
After washing with tap water, sections were counterstained with methyl green for 
nuclei on a heating plate (60°C), progressively dehydrated and coverslipped. 
3.8.  Vascular Morphometry  
The degree of muscularization was determined from 3 μm mouse lung sections. 
Morphological assessment of lung vessel muscularization (outer diameter: 10-20 
m, 20-70 m, 70-150 m and >150m) was performed via computer-assisted 
analysis (Leica Q Win Standard analyzing software) at 40x or 63x magnification 
under a microscope. The analytical software detected the vessels’ endothelium 
that appeared in a brown color (vWF staining) and the muscle tissue surrounding 
the vessels that appeared in a violet color (-SMA staining). The software 
distinguished between non-muscularized vessels (no smooth muscle cells 
detectable with -SMA staining), partially muscularized (minimum one smooth 
muscle cell and maximum 75% of the vessel circumference with -SMA staining), 
and fully muscularized (>75% of the vessel circumference with -SMA staining). 
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The vascular morphometry was carried out by a technician. 
3.9.  Isolation of primary alveolar type II cells  
AEC II cells were isolated according to a protocol published by Seimetz and 
colleagues (Seimetz et al., 2011). The whole lung was perfused with 1 ml PBS 
through the right ventricle to remove the intrapulmonal blood cells. Lungs were 
perfused with 1 ml Dispase through the trachea and the trachea was tied off with a 
string. Lungs were digested in 2 ml Dispase for 30 min at 37°C and minced. The 
suspension was sequentially filtered through 70, 40, and 10 μm nylon meshes and 
then centrifuged at 200 g for 10 min. The pellet was resuspended in Dulbecco's 
modified eagle medium (Invitrogen, Karlsruhe, Germany), and negative selection 
for lymphocytes/macrophages was performed by incubation on CD16/32- and 
CD45-coated Petri dishes for 45 min at 37°C. Negative selection for fibroblasts was 
performed by adherence for 45 min at 37°C on uncoated cell-culture dishes. Cell 
purity was analyzed in freshly isolated AECII cells directly after isolation by 
epithelial cell morphology and immunofluorescence analysis with Nile red. AECII 
cells used throughout this study demonstrated 95% ± 3% purity. The isolation was 
performed with the help of a technician since several samples needed to be taken 
care of at the same time. 
3.10.  Microarray experiments  
RNA was purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following 
the kit instructions. RNA quality was assessed by capillary electrophoresis using 
the Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Purified total 
RNA was amplified and Cy5-labeled using the LIRAK kit (Agilent) according to the 
kit instructions. Per reaction, 200 ng of total RNA was used. The Cy-labeled aRNA 
was hybridized overnight to 8 x 60K 60mer oligonucleotide spotted microarray 
slides (Agilent Technologies, design ID 028005). Hybridization and subsequent 
washing and drying of the slides were performed following the Agilent hybridization 
protocol. The dried slides were scanned at 2 mm/pixel resolution using the 
InnoScan is900 (Innopsys, Carbonne, France). Image analysis was performed with 
Mapix 6.5.0 software, and calculated values for all spots were saved as GenePix 
results files. Stored data were evaluated using the R software and the limma 
package from BioConductor (Gentleman et al., 2004). Log mean spot signals were 
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taken for further analysis. Data was quantile-normalized before averaging. Genes 
were ranked for differential expression using a moderated t-statistic (Smyth, 2004). 
Pathway analyses were done using gene set tests on the ranks of the t-values. 
RNA samples were given to Dr. Jochen Wilhelm and microarray experiments were 
performed in his laboratory. 
3.11.  Western blotting  
Loading buffer was added to protein samples from the lungs (5% SDS in 
bromophenol blue and -mercaptoethanol), denatured for 8 min at 98°C and 
cooled on ice. 8 g of protein sample was loaded on a 10% polyacrylamide gel and 
run at 35 mA per gel for approximately 1 h. Samples were then electrically 
transferred to a polyvinylidene fluoride (PVDF) membrane (Amersham) by semi-dry 
electro blotting (70 mA per Gel; gel size: 7 x 9 cm) for 90 min. The membrane was 
blocked with 5% milk in TBS-T blocking buffer at RT on a shaker for 1 h followed 
by incubation with primary antibody (Table 6) overnight at 4°C. After washing with 
1x TBS-T four times for 15 min each, the membrane was incubated with the 
respective HRP-labeled secondary antibody (dilution 1:2000) at RT for 1 h followed 
by four times washing with 1x TBS-T buffer for 15 min each. The protein bands 
were detected by ECL (Enhanced Chemi-luminescence, Amersham, Germany) 
treatment, followed by exposure of the membrane.  
Table 6. Antibodies for western blot. 
Primary 
antibody 
(rabbit) 
Company 
(Catalog 
number) 
Dilution Secondary 
antibody 
Company 
(Catalog 
number) 
Dilution 
FGF10 Abcam 
(ab71794) 
1:1000 Swine anti rabbit 
HRP 
Dako 
(P0217) 
1:2000 
FGFR2 Santa Cruz 
(sc-122) 
1:200 Swine anti rabbit 
HRP 
Dako 
(P0217) 
1:2000 
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Primary 
antibody 
(rabbit) 
Company 
(Catalog 
number) 
Dilution Secondary 
antibody 
Company 
(Catalog 
number) 
Dilution 
Mature 
SFTPC 
Seven Hills 
(WRAB-
76694) 
1:3000 Swine anti rabbit 
HRP 
Dako 
(P0217) 
1:2000 
Pro + 
Mature 
SFTPB 
Abcam (ab 
40876) 
1:2000 Goat anti rabbit 
HRP 
Abcam (ab 
6721) 
1:5000 
B-ACTIN Abcam 
(ab8227) 
1:30.000 Swine anti rabbit 
HRP 
Dako 
(P0217) 
1:2000 
 
3.12.  Flow cytometry and Fluorescence Activated Cell Sorting 
analysis 
Whole lungs were isolated in ice-cold Hankʼs balanced salt solution (HBSS). Then, 
lobes were chopped finely using sterile razor blades, digested in a 10 mL solution 
of 0.5% collagenase in HBSS on a heating plate (40°C) stirring 700 rpm for 60 min. 
Once the homogenate was dissociated, the cell suspension was successively 
passed through 20G, 24G, and 26G needles, then strained on 70 μm and 40 μm 
filters. One volume HBSS was added to dilute collagenase and cell suspensions 
were centrifuged at 1500 rpm for 5 min to remove the enzyme solution. Cells were 
then resuspended in 500 μL 10% FCS in DMEM and stained with fluorochrome-
labeled anti-mouse antibodies for 20 min at 4°C (Table 7), followed by washing and 
flow cytometric analysis with LSR Fortessa equipped with FACSDiva™ software 
(BD Bioscience). Flow cytometry analysis with LSR Fortessa were done by Dr. 
Jennifer Quantius. 
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Table 7. Antibodies for flow cytometry/FACS.  
Antibody Company 
(Catalog number) 
Dilution 
Anti-Prosurfactant Protein C (proSP-C) 
Antibody 
Millipore (AB3786) 1:500 
T1alpha (Podoplanin) APC anti-mouse Biolegend 
(127409) 
1:20 
 
EpCAM (CD326) APC/Cy7 Biolegend 
(118217) 
1:50 
Alexa Fluor 488 anti-mouse CD31 
Antibody 
Biolegend 
(102431) 
1:50 
BD Pharmingen FITC Rat Anti-Mouse 
CD45 (clone 30-F11) 
BD Biosciences 
(553079) 
1:50 
PE anti-human/mouse CD49f Antibody Biolegend 
(313611) 
1:50 
Pacific Blue anti-mouse Ly-6A/E (Sca-1) 
Antibody 
Biolegend 
(108119) 
1:50 
PE/Cy7 anti-mouse CD24 Antibody Biolegend 
(101821) 
1:200 
Rabbit serum Sigma-Aldrich 
(R9133) 
1:500 
F(ab´)2-Goat anti-Rabbit IgG (H+L) 
Secondary Antibody, Alexa Fluor 555 
conjugate 
ThermoFisher 
Scientific (A-
21430) 
1:1000 
Neg. control for T1alpha: APC Syrian 
Hamster IgG Isotype control 
Biolegend 
(402012) 
1:20 
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3.13.  Alveolar morphometry 
For alveolar morphometry, lungs were flushed subsequently with PBS and 4% 
paraformaldehyde in phosphate-buffered saline (pH 7.0) at a vascular pressure of 
20 cm H2O. Then PBS was infused via the trachea at a pressure of 20 cm H2O and 
fixed with 4% paraformaldehyde in phosphate-buffered saline (pH 7.0) via the 
trachea at a pressure of 20 cm H2O. Investigations were performed using 5 μm 
sections of paraffin-embedded left lobe of the lungs. The mean linear intercept, 
mean air space, and mean septal wall thickness were measured after staining with 
hematoxylin and eosin (HE). Total scans from the left lobe were analyzed using a 
Leica DM6000B microscope with an automated stage according to the procedure 
previously described (McGrath-Morrow et al., 2004; Woyda et al., 2009), which 
was implemented into the Qwin V3 software (Leica, Wetzlar, Germany). Horizontal 
lines (distance 40 μm) were placed across each lung section. The number of times 
the lines cross alveolar walls was calculated by multiplying the length of the 
horizontal lines and the number of lines per section then dividing by the number of 
intercepts. Bronchi and vessels above 50 μm in diameter were excluded prior to 
the computerized measurement. The air space was determined as the 
nonparenchymatous nonstained area. The septal wall thickness was measured as 
the length of the line perpendicularly crossing a septum. From the respective 
measurements, mean values were calculated. 
3.14.  Lung function measurement 
The Mice were anaesthezised by intraperitoneal injection of a solution of 1.2 l/g 
body weight of ketamin 10% and 0.6 l/g body weight of Dormitor (1mg/ml). 
Deepness of anaesthesia was assessed by toe pinching. Then, incision of the skin 
was made at the level of larynx to access the trachea without opening the chest 
cavity. Horizontal tracheal incision was made to intubate the mouse and connect it 
to the flexivent fx1 (Scireq, Montreal, Canada) for lung function measurement 
(compliance, elastance and resistance). Each mouse, eight measurements of each 
10 sec were performed and mean values were calculated. 
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3.15. Statistical analyses and figure assembly 
Significance was determined by two-tailed Student´s t-test using GraphPad PRISM 
statistical analysis software. All data are presented as mean  SEM. Values of 
p<0.05 were considered significant. Figures were assembled by using Adobe 
illustrator software. 
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4.   Results  
4.1.  Validation of the BPD mouse model 
First, we established and validated the BPD mouse model using hyperoxia-induced 
lung injury in neonatal mice leading to hypoalveologenesis. Wildtype pups were 
exposed to either normoxia or hyperoxia (85% oxygen) from P0 until P8 (Figure 
5A). Lungs were analysed at P2, P5 and P8 by using H&E staining and alveolar 
morphometry. Compared to the normoxia group, lungs that were exposed to 
hyperoxia already revealed a macroscopically decrease in alveolar septation at P2 
which became more obvious at P8 (Figure 5B). While, in the alveolar stage, the 
neonatal lung forms multiple alveoli in normoxia in a process called “secondary 
septa formation”, this process is significantly impaired in hyperoxia leading to 
dilated alveolar sacs, which lack secondary septa. This observation was confirmed 
by unbiased analysis using alveolar morphometry. Comparing hyperoxia group 
versus normoxia group the difference in mean linear intercept was constantly 
increasing during the time course of hyperoxia and became significant at P8 
(Figure 5C). Accordingly, the airspace was higher in the hyperoxia group compared 
to the normoxia group but not significantly. The septal wall thickness did not show 
substantial differences in both groups. 
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Figure 5. Validation of the HOX injury model to trigger hypoalveologenesis. 
(A) Experimental approach. WT animals (C57BL/6) were subjected to HOX (85% 
O2) or NOX (21% O2) for up to 8 days. (B) Corresponding H&E staining at P2, P5 
and P8 showing progressive defects in alveologenesis. (C) Morphometry for MLI, 
Airspace and Septal wall thickness showing significant increase in MLI at P8. Scale 
bars main images: 500 m, insets in images: 50 m. 
 
4.2. Neonatal Fgf10 expression in the wild type lung is low in 
normoxia and decrease significantly upon hyperoxia 
Using qPCR, we first examined the expression level of Fgf10 as well as associated 
Fgf genes of the same Fgf subfamily (Fgf1, Fgf3 and Fgf 7) in the lungs of 
C57BL/6 wild type (WT) pups at different time points during normal alveologenesis 
(between P0 and P35). These genes encode for FGF ligands acting via FGFR2b 
(Itoh & Ornitz, 2008). When normalized to their respective values for the first 
timepoint collected (P0), the results indicated a decrease in Fgf10 expression over 
time, while the other FGFR2b ligands were maintained at stable levels (Figure 
6Aa). Compared to Fgf10 expression, Fgf1 and Fgf7 showed higher expressions 
while Fgf3 was generally expressed at lower levels (Figure 6Ab). The examination 
of the expression (normalized to the first timepoint collected, P2) of these ligands in 
hyperoxia (HOX) (85% O2 from P0 onwards) revealed Fgf10 as the only FGFR2b 
ligand whose expression was significantly reduced at P5 and P8 compared to 
normoxia (NOX)-exposed WT lungs (Figure 6Ac). 
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Figure 6. Postnatal Fgf10 expression in normoxia and hyperoxia.  
RT-qPCR for Fgf1, 3, 7 and 10 in lungs at various postnatal stages in normoxia 
(NOX). (A) Normalization to P0 for each of the ligands indicates that Fgf10 
expression decreases postnatally compared to P0 and compared to the other 
ligands. (B) Normalization to Fgf10 expression at each time point indicates that 
Fgf1 and Fgf7 are expressed at higher levels than Fgf10. (C) Comparison of 
FGFR2b ligands in hyperoxia (HOX) versus NOX indicates that Fgf10 is the only 
gene, which decreases significantly upon HOX injury.  
 
4.3.  Effect of constitutive Fgf10 deficiency on embryonic lung 
development at E12.5 and E18.5  
4.3.1.  Fgf10+/- mice show significant decrease in Fgf10 expression, delayed 
branching morphogenesis due to decreased proliferation of the 
epithelium  
Considering the previously reported decreased FGF10 protein in human patients 
with BPD, we investigated whether Fgf10 deficiency in mice could be causative of 
the clinical complications observed in BPD. We therefore crossed Fgf10+/- males 
and WT females (both on the C57BL/6 background) to generate several litters of 
Fgf10+/- experimental and Fgf10+/+ (WT) control embryonic and newborn littermate 
mice. We collected embryos at E12.5 (n=3 and n=4 for WT and Fgf10+/-, 
respectively) and E18.5 (n=3 and n=7 for WT and Fgf10+/-, respectively) and 
assessed levels of Fgf10 mRNA expression in their lungs by qPCR. Our results 
indicate 23.7% and 57.9% reduction in Fgf10 expression at E12.5 and E18.5 
(p=0.04 and p=0.01, respectively) in Fgf10+/- versus WT lungs (Figure 7A). 
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Furthermore, embryonic lungs at E12.5 revealed a significant delay in branching 
morphogenesis in Fgf10+/- versus WT lungs, most likely due to decreased 
proliferation of the epithelium (Figure 7B-E). Flow cytometry analysis of the lung at 
E18.5 showed significant decreased number of AECII but an increase in AECI 
Fgf10+/- versus WT lungs (Figure 7F). 
   
Figure 7. Constitutive Fgf10 deficiency leads to delayed branching due to 
defects of the epithelium.  
(A) Fgf10 heterozygous lungs display decreased levels of Fgf10 mRNA expression 
and (B) decreased epithelial branching at E12.5 (see (C) for quantification), 
associated with (D) decreased proliferation of the epithelium (see (E) for 
quantification). (F) At E18.5 Fgf10+/- lungs display decreased EPCAM-positive cells 
associated with a decrease in AECII and increase in AECI. 
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4.3.2.  Fgf10+/- mice show impaired lung morphology and differential gene 
expression 
We next examined the presence of potential lung defects in Fgf10+/- embryos at 
E18.5. We made use of previously described Fgf10Lacz/- hypomorphic mutants 
(Ramasamy et al., 2007b). These two lines exhibit 50% and 20% Fgf10 expression 
compared to WT lungs, respectively. Figures 8Aa-c show the histology of the 
E18.5 WT (n=3), Fgf10+/- (n=7), and Fgf10Lacz/- hypomorphic (n=3) lungs. 
Quantification of the morphological defects (Figure 8B) indicated that Fgf10+/- lungs 
exhibited increased MLI and airspace with no change in septal wall thickness 
compared to WT. Interestingly, Fgf10Lacz/- hypomorphic lungs mostly showed 
increased septal wall thickness with moderate but significant increase in MLI. The 
reason for this difference is unclear.  
In order to further characterize the nature of the lung morphological differences 
between the three conditions, we isolated RNA from WT (n=3), Fgf10+/- (n=7) and 
Fgf10Lacz/- hypomorphic (n=3) E18.5 lungs and carried out transcriptome analyses. 
Our approach using two distinct types of Fgf10 mutants with different Fgf10 levels 
allowed us to identify the top 70 genes (selected based on p-value), which were 
differentially regulated between Fgf10Lacz/- hypomorph and WT lungs and then to 
compare the expression of these selected genes between Fgf10+/- and WT lungs. 
The heat map in Figure 8Ca shows that these genes were indeed also similarly 
decreased or increased in Fgf10+/- versus WT lungs. The graph in Figure 8Cb 
summarizes the different cellular compartments and biological processes, which 
are potentially affected based on the known function of the identified genes. 
Interestingly, the expected epithelial defects of Fgf10 deficiency could be caused 
partially by the dysregulated expression of a number of identified epithelium-
specific genes, such as lysophosphatidylcholine acyltransferase 1 (Lpcat1), 
phosphatidylisnositol-4-Phosphate 5-kinase, type I, alpha (Pip5k1a), G-protein-
coupled receptor 30 (Gpr30), Calpain 6 (Capn6) and Pleiotrophin (Ptn). In 
particular, Lpcat1 deficiency has been associated with neonatal death due to 
surfactant defects (Bridges et al., 2010), while Ptn promotes alveolar epithelial type 
II (AECII) cell proliferation and prevents their differentiation into AECI (Weng et al., 
2009). In addition to those implicated in epithelial defects, we also identified 
changes in genes expressed in muscle, the immune system, nerves and the ECM 
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(Figure 8Cc). As a consequence of either direct or indirect effects of Fgf10 on the 
different cellular compartments, these results highlight potential defects of Fgf10+/- 
lungs. Another project performed in our laboratory using qPCR to validate the 
changes in FGF signaling and the associated epithelial markers between Fgf10+/- 
and WT lungs at E18.5 showed significant decreased mRNA level of Fgfr2b and 
Bmp4, the latter a downstream target of FGF10 in the epithelium (data not shown). 
An overall trend of decreasing expression was also observed in other epithelial 
markers. Epcam expression was significantly reduced supporting alterations in the 
epithelial compartment, which is the main cellular target of FGF10 signaling. As 
FGF10 and TGF-1 play opposite roles during lung development, we also 
investigated the expression of genes involved in TGF- signaling and the 
associated ECM. We found significantly increased Smad3, Smad7 and IL-1 
expression, but no changes in Tgf-1 and Tgf-3. Additionally, the expression of 
different forms of collagens (Col1a1, Col1a2, Col3a1, Col5a2) showed increasing 
trends (data not shown).  
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Figure 8. E18.5 Fgf10+/- lungs display perturbed morphometry and impaired 
gene expression.  
(A) Haematoxylin/eosin staining of (a) Fgf10+/+ (b) Fgf10+/- (c) and Fgf10Lacz/- lungs 
at E18.5. (B) Morphometry of the lungs shown in (A). Note the increase in (a) MLI, 
(b) airspace and no change in (b) septal wall thickness in Fgf10+/- lungs compared 
to Fgf10+/+ (C) (a) Gene array-based/Heat map analysis of the whole lung of E18.5 
Fgf10+/+, Fgf10+/- and Fgf10Lacz/- lungs indicating that Fgf10 deficient lungs display 
an impaired pattern of gene expression compared to Fgf10+/+ lungs (see Figure S2 
for greater magnification). (b) Symbolic representation of the genes affected 
grouped by cell types or processes. (c) Some of the relevant genes pertinent for 
the Epithelium, Muscle, Immune system, Nerve and ECM are listed. Scale bar Aa-
c: 125 µm, inserts: 30 µm. 
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4.4.  Effect of constitutive Fgf10 deficiency on neonatal response to 
hyperoxia lung injury: Characterization of defects 
4.4.1.  Fgf10+/- mice reveal 100% lethality and significant defects in lung 
morphology upon neonatal hyperoxia lung injury 
Before we tested the response of Fgf10+/- and the corresponding WT controls to 
HOX, we first analyzed Fgf10+/- (n=10) and WT (n=12) pups exposed to room air 
(normoxia) between P0 and P8 (Figure 9A). Newborn Fgf10+/- mice exposed to 
room air were completely viable. No macroscopic differences were observed 
between Fgf10+/- and WT littermates (data not shown). Morphometric analysis of 
P3 lungs (Figure 9Bb,d versus a,c, n=4 for each genotype) showed no significant 
differences between Fgf10+/- and WT for the mean linear intercept (MLI), airspace 
or septal wall thickness (Figure 9Ca-c). Our present results therefore show that at 
E18.5, morphometric analyzes reveal differences between the two genotypes. 
However, at P3, there is no obvious difference between Fgf10+/- and Fgf10+/+ in 
NOX. The cellular and molecular mechanisms involved in this apparent recovery 
from E18.5 to P3 are still unknown. 
To mimic the BPD phenotype, newborn pups were subjected to hyperoxia injury 
(85% oxygen) for up to 8 days (Figure 9D). In WT animals, this oxygen 
concentration is known to induce a BPD-like phenotype characterized by 
hypoalveolization (Berger & Bhandari, 2014) (see also Figure 5 for the validation of 
the model under our experimental conditions.). Two litters were generated and 
identical results were obtained. Figure 9E-G displays the results from one litter (14 
pups). Survival analysis showed that 100% of the WT mice survived at day 8 while 
none of the Fgf10+/- experimental mice were alive at this time point. 50% lethality 
was observed already at P5, suggesting that damage to the lungs in Fgf10+/- 
neonates start earlier than P5 (Figure 9E). We therefore analyzed WT and Fgf10+/- 
lungs at postnatal day 3 (P3) during the course of HOX. At P3, hematoxylin-eosin 
staining of Fgf10+/- lungs (n=4) revealed an abnormal phenotype compared to WT 
lungs, with enlarged alveolar sacs and thinner interalveolar walls (Figure 9Fb,d 
versus a,c). Morphometric analysis demonstrated significant increase in MLI and 
airspace (both p=0.001) as well as decreased septal wall thickness (p=0.039) 
(Figure 9Ga-c). In conclusion, our results demonstrate that constitutive Fgf10 
deficiency leads to massive lethality of the pups upon HOX exposure. The 
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following experiments are designed to identify the onset, and the nature, of defects 
in Fgf10+/- lungs. 
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Figure 9. Constitutive Fgf10 deficiency leads to neonatal death upon 
hyperoxia injury.  
(A) Experimental set-up for NOX of Fgf10+/- (experimental group) and Fgf10+/+ 
(control group) animals. (B) Haematoxylin/eosin staining of NOX exposed (a,c) 
control or (b,d) experimental lungs at P3. (C) Corresponding lung morphometric 
analysis. Note the absence of difference in (a) MLI, (b) airspace and (c) septal wall 
thickness. (D) Experimental set up for HOX of Fgf10+/- (experimental group) and 
Fgf10+/+ (control group) animals. (E) Survival curve for HOX-exposed animals 
showing that all of the experimental animals died within 8 d, whereas all of the 
control animals survived. (F) Haematoxylin/eosin staining of HOX exposed (a,c) 
control or (b,d) experimental lungs at P3. (G) Corresponding lung morphometric 
analysis of HOX-exposed control and experimental animals. Note the increase in 
(a) MLI, (b) airspace and the decrease in (c) septal wall thickness. Scale bar for 
Ba,b: 500 µm, Bc,d: 50 µm, Fa,b: 500 µm and Fc,d: 50 µm 
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4.4.1.1.  Adult Fgf10+/- mice in normoxia reveal impaired lung morphology 
and lung function at P70  
Whereas there is no change in lung morphology at P3 in Fgf10+/- versus WT lungs 
(Figure 9B+C), the airspace is significantly decreased and the septal wall thickness 
is significantly increased in Fgf10+/- lungs at P70 (Figure 10A+B, WT n=4, Fgf10+/- 
n=3). Interestingly, this morphological change is associated with impaired lung 
function due to decrease in compliance and increase in elastance, while the 
resistance parameter does not change significantly (Figure 10C). Despite of the 
impaired lung function we did not observe any obvious reduction in activity or other 
changes in the appearance of the Fgf10+/- mice compared to WT mice. These data 
suggest a higher susceptibility of the lung tissue to the aging process in Fgf10+/- 
mice versus WT mice. A reduced regenerative capacity due to defects of stem/ 
progenitor cells could be a reason. 
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Figure 10.  Constitutive Fgf10 deficiency leads to impaired lung morphology 
and lung function at P70.  
(A) Haematoxylin/eosin staining of NOX exposed (a,c) control or (b,d) 
experimental lungs at P70. (B) Corresponding lung morphometric analysis. Note 
the decreased (b) airspace and increased (c) septal wall thickness. (C) Lung 
function parameters at P70 reveals decreased (a) compliance, (b) increased 
elastance and no changes for (c) resistance. Scale bar for Aa,b: 500 µm, Ac,d: 50 
µm.  
 
4.4.2.  Qualitative defects of AEC II cells 
Our previous results suggested that Fgf10+/- lungs displayed epithelial 
abnormalities (Figure 7D). During lung development, the distal epithelium 
expressing FGFR2b responds to FGF10 secreted by the mesenchyme. It has been 
proposed that FGF10 signaling maintains the differentiation of the multipotent 
epithelial progenitors (positive for the transcription factors ID2, SOX9 and NKX2.1) 
(El Agha & Bellusci, 2014; Ramasamy et al., 2007; Volckaert et al., 2013). 
Interestingly, lineage tracing with the Id2-CreERT2 driver line indicated that these 
multipotent progenitors give rise to AECI and AECII cells (Rawlins et al., 2009). 
Recently, single cell transcriptome analysis of the epithelium during lung 
development showed that AECI and AECII arise from a common bipotent epithelial 
progenitor pool, itself arising from the multipotent epithelial progenitor pool. In 
addition to the identification of a specific gene-set signature for AECI and AECII 
cells, which allows for a better characterization of these alveolar cells, this work 
showed that the bipotent progenitors expressed both gene-set signatures 
(Treutlein et al., 2014; Desai et al., 2014).  
In order to define the contribution of AECII in the lethal phenotype observed in 
Fgf10+/- lungs, we isolated AECII from Fgf10+/- and WT P3 lungs in NOX and HOX 
conditions and compared their respective transcriptomes (see also supplementary 
material, Figure S1). In particular, we carried out an interaction "HOX x genotype" 
analysis. The volcano plot identified a set of genes that are either up- or down-
regulated (Figure 11A). Interestingly, the majority of differences between the 
genotypes could be noted in the downregulated genes. The top 100 regulated 
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genes according to their p-values are represented in the corresponding heat maps 
(Figure 11Ba,b, see supplementary material, Figure S2 for greater magnification). 
We found a gene set (located in the lower part of the array) the expression of 
which was not drastically changed in HOX between the two genotypes (Figure 
11Ba), but was differentially regulated in NOX conditions (Figure 11Bb). 
Furthermore, another gene set which was downregulated in HOX (located in the 
top part of the array) was upregulated in NOX conditions. KEGG analysis revealed 
that the altered processes were almost all linked to the immune system, and were 
downregulated in mutant AECII cells (Figure 11C). These processes were: 
systemic lupus erythematous, staphylococcus aureus infection, antigen 
presentation, graft versus host disease, and autoimmune thyroid disease, amongst 
others. In order to assess the differentiation status of the isolated AECII cells in 
Fgf10+/- versus WT lungs, we analysed the expression of the previously reported 
signatures for AECII and AECI (Treutlein et al., 2014) in the arrays generated from 
these cells in both NOX (Figure 11D) and HOX conditions (Figure 11E) (see 
supplementary material, Figure S3 for greater magnification.). In both conditions, 
we found a decrease in the AECII signature, with a corresponding increase in the 
AECI signature. Figure 11F, which shows a comparison of the differential 
expression between genotypes in HOX versus NOX confirms the differential 
clustering of the signatures for AECI and AECII.  
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Figure 11. Interaction "hyperoxia x genotype" analysis to identify the 
significant genes/pathways differentially affected by HOX in isolated AECII 
cells from WT and Fgf10+/- lungs at P3.  
(A) Volcano plot. (B) Top 100 regulated genes in (a) HOX versus (b) NOX in AECII 
cells isolated from Fgf10+/- and WT mice (see Figure S2 for greater magnification). 
(C) KEGG analysis of the interaction "hyperoxia x genotype". (D) AECI and AECII 
gene-set analysis comparing AECII cells isolated from Fgf10+/- and WT lungs in 
NOX (see Figure S3 for greater magnification). (E) AECI and AECII gene-set 
analysis comparing AECII cells isolated from Fgf10+/- and WT lungs in HOX. (see 
Figure S3 for greater magnification). (F) AECI and AECII gene-set analysis in 
AECII cells isolated from Fgf10+/- versus WT lungs in HOX or NOX. 
 
Results 
 
52 
4.4.3.  Fgf10+/- lungs in the context of HOX exhibit decreased mature SFTPC 
expression associated with quantitative defects of AECII 
Using western blotting (whole lung homogenates, n=4 for WT and n=3 for Fgf10+/- 
lungs at P3, Figure 12Aa,b) we quantified the protein expression of FGF10, FGFR2 
(using an antibody which does not discriminate between the FGFR2b versus the 
FGFR2c isoform) and mature SFTPC and SFTPB. We noted a significantly 
reduced expression of all these markers in Fgf10+/- versus WT (Figure 12Ac-f).  
Next, we investigated by FACS the number of total epithelial cells (using EpCAM 
as a general marker), AECI (T1-positive), AECII (SFTPC-positive) and epithelial 
stem progenitor cells (EpiSPC, EpCAMhigh CD24low). In NOX, we observed a 
significant decrease in the ratio of EpCAM-positive cells over the total cell number 
in Fgf10+/- versus WT lungs (Figure 12Ba). Interestingly, rather than a global 
decrease in the ratio of AECI and AECII over the total number of cells in the 
Fgf10+/- versus WT lungs, we noted an increase in the ratio of AECI (Figure 12Bb) 
and an associated decrease in the ratio of AECII cells (Figure 12Bc) in the Fgf10+/- 
versus WT lungs. This observation has been confirmed in 10 weeks (P70) old 
Fgf10+/- versus WT lungs (Figure S4). This suggests that Fgf10 deficiency leads to 
substantial differentiation of the previously identified bipotent progenitor cells along 
the AECI lineage at the expense of the AECII lineage. This defect is in addition to 
the previously described impaired differentiation of the AECII cells in Fgf10+/- 
versus WT P3 lungs (Figure 11D-F). Interestingly, no difference was observed in 
the ratio of EpiSPC cells over the EpCAM high population in Fgf10+/- versus WT 
lungs (Figure 12Bd). Following hyperoxia injury, the ratio of epithelial cells 
(EpCAM+) in Fgf10+/- versus WT was no longer significant, suggesting 
compensatory proliferative events in Fgf10+/- (Figure 12Be). However, the 
quantitative imbalance in AECI ratio in Fgf10+/- versus WT remained (Figure 12Bf), 
while the AECII (SFTPC-positive) ratio in Fgf10+/- versus WT was no longer 
significant (Figure 12Bg). This suggests that the AECII pool in Fgf10+/- is partially 
replenished upon HOX. As for NOX, no difference was observed in the ratio of 
EpiSPC cells in Fgf10+/- versus WT (Figure 12Bh). Investigating changes in the 
mesenchyme revealed significant increases in NOX, for the fraction of CD45-, 
CD31-, and EpCAM- over total cells in Fgf10+/- versus WT lungs (Figure S5Aa). 
This increase likely reflects the reduced number of epithelial cells. This difference 
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in the number of mesenchymal cells between the two genotypes was no longer 
detected in HOX (Figure S5Ab). Quantification of the ratio of hematopoietic and 
endothelial cells (defined as CD45-positive, CD31-positive, EpCAM-negative) by 
FACS showed no difference in NOX and HOX between Fgf10+/- and WT lungs at 
P3 (Figure S5B), suggesting no significant inflammation in Fgf10+/- versus WT at 
this stage. 
 
Figure 12. Fgf10+/-  lungs in the context of HOX exhibit less mature-SFTPC 
and mature-SFTPB.  
(A) Western blotting analysis (whole lung homogenates) for (a) FGF10, FGFR2, 
mature-SFTPC and -ACTIN as well as (b) mature-SFTPB and -ACTIN on 
Fgf10+/+  and Fgf10+/-  lungs exposed to HOX at P3. (c-f) Quantification of bands 
using ImageJ software. (B) Fluorescence Activated Cell Sorting in NOX (a-d) and 
HOX (e-h) of Fgf10+/+ and Fgf10+/-  P3 lungs for (a,e) epithelial cells (EpCAM+), 
(b,f) AECI, (c,g) AECII and (d,h) epithelial stem progenitor cells (EpiSPC).  
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4.4.4.  Blood vessel numbers and their muscularization are 
indistinguishable between Fgf10+/- versus WT lungs in NOX 
Vascular morphometry analysis at P3, to quantify the number of vessels and extent 
of muscularization of these vessels, was performed. Vessels were subdivided into 
four groups based on their diameters (10-20 µm, 20-70 µm, 70-150 µm and >150 
µm). While no difference in total vessel count was noted, a substantial reduction 
was observed in the number of 70-150 µm vessels between Fgf10+/- versus WT in 
NOX (p=0.049) (Figure 13A). No difference in muscularization between Fgf10+/- 
and WT lungs was noted (Figure 13Ea-d). 
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Figure 13: Analysis of the vascular defects in P3 Fgf10+/- versus Fgf10+/+ (WT) 
in HOX indicates that Fgf10+/- vessels are more sensitive to HOX injury and 
exhibit a less muscularized phenotype.  
(A) Total vessel count in NOX between P3 Fgf10+/+ and Fgf10+/- lungs. No 
significant difference is observed. (B) Total vessel count in HOX between P3 
Fgf10+/+ and Fgf10+/- lungs. There is a decreasing trend in the total number of blood 
vessels in Fgf10+/- lungs as well as for the group of blood vessel with 20-70 µm 
diameter. (C+D) Total vessel count between NOX and HOX in (C) Fgf10+/+ and (D) 
Fgf10+/- lungs. Note the decrease in the number of blood vessels displaying a 20-
70 µm and 70-150 µm diameter upon HOX for both Fgf10+/+ and Fgf10+/- lungs. 
Note also the significant decrease in the total number of blood vessels of all 
diameters included in (D) Fgf10+/- lungs, suggesting that the blood vessels in 
Fgf10+/- lungs are more sensitive to HOX. (E) Blood vessel muscularization in 
normoxia between Fgf10+/+ and Fgf10+/- lungs for blood vessels at (a) 10-20 µm, 
(b) 20-70 µm, (c) 70-150 µm and (d)>150 µm. No significant difference is 
observed. (F) Blood vessel muscularization in hyperoxia between Fgf10+/+ and 
Fgf10+/- lungs for blood vessels at (a) 10-20 µm, (b) 20-70 µm, (c) 70-150 µm and 
(d)>150 µm. Note that for the 20-70 µm and 70-150 µm, there is a decrease in the 
partially muscularized vessels and an increase in the number of non-muscularized 
vessels between the Fgf10+/- and Fgf10+/+ lungs indicating a less muscularized, 
more immature vascular phenotype in Fgf10+/- lungs.  
 
4.4.5.  A trend towards decreased number of blood vessels and decreased 
muscularization is observed in Fgf10+/- versus WT lungs exposed to 
HOX 
We first compared the number of blood vessels in Fgf10+/- versus WT lungs in HOX 
(Figure 13B). We observed a trend towards a decrease in total blood vessel count 
in Fgf10+/- with the 20-70 µm blood vessels being the most affected. Next, we 
compared the number of blood vessels in WT and Fgf10+/- in HOX versus NOX 
(Figure 13C). In WT lungs, we observed a trend towards a drop in total blood 
vessel count upon HOX injury, the 20-70 µm blood vessels being the most affected 
(Figure 13C). Interestingly, in WT lungs, HOX significantly increased the number of 
70-150 µm blood vessels (p=0.0009). In Fgf10+/- lungs, HOX significantly reduced 
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the total blood vessel count (p=0.01) (Figure 13D). As for the WT, we observed a 
decrease in the number of 20-70 µm blood vessels (p=0.0079) and an increase in 
the number of 70-150 µm blood vessels (p=0.0198). Finally, we analyzed blood 
vessel muscularization (Figure 13Fa-d). A major loss of muscularization was seen 
for the group of blood vessel with 20-70 µm diameter (Figure 13Fb) and a trend 
towards reduction was observed for the blood vessels with 70-150 µm diameter. In 
spite of these defects, we failed to see any evidence of lung hemorrhage in Fgf10+/- 
lungs in HOX (either at P3, P5, or P8, data not shown), which suggests that the 
contribution of the vascular system to the lethal phenotype is likely minor in our 
experimental conditions.  
4.5.  Effect of blockade of FGFR2b ligands in normoxia and 
hyperoxia  
4.5.1.  Attenuation of FGFR2b ligands during the pseudoglandular (E14.5) 
and saccular (E16.5) stage of embryonic lung development affects 
alveolar lineage formation 
In order to confirm what we observed in the constitutive Fgf10 deficient mice, we 
tested functionally the role of FGF signaling during embryonic alveolar lineage 
formation. We used a previously reported dominant negative soluble Fgfr2b 
expression approach (Rosa26rtTA/+;Tg(tet(O)sFgfr2b)/+ mice) to trap, in an 
ubiquitous and doxycycline-based inducible manner, all the FGFR2b ligands, 
thereby turning off FGFR2b signaling mediated by FGF1, 3, 7 and 10 (see Figure 
6) (Al Alam et al., 2015; Volckaert et al., 2011; Danopoulos et al., 2013; MacKenzie 
et al., 2015; Parsa et al., 2010; Parsa et al., 2008). In this first functional in vivo 
experiment, we attenuated FGFR2b signaling from E14.5 to E18.5 (Figure 14A). 
The examination of the experimental (n=3) and control lungs (n=4) revealed 
abnormal lung development with delayed growth as well as quantitatively 
decreased and dilated epithelial end buds (Figure 14B). The epithelial (EpCAM-
positive), AECI (T1-positive) and AECII (SFTPC-positive) cell populations were 
validated by FACS (Figure 14C). In spite of a total reduction of EpCAM-positive 
cells by 300% in experimental versus control lungs (data not shown), the EpCAM-
positive/whole lung homogenate ratio did not change between experimental and 
control lung but a clear reduction of the ratio of AECI and AECII (to the total 
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number of EpCAM+ cells) was observed indicating aborted alveolar lineage 
formation. 
 
Figure 14. Inhibition of FGFR2b signaling from E14.5 to E18.5 leads to 
impaired AECI and AECII formation.  
(A) Experimental approach. Pregnant females carrying control and experimental 
embryos were given doxycycline intraperitoneally and via food from E14.5 to 
E18.5. (B) Appearance of the control and experimental lungs at E18.5. Note the 
reduced size and dilated branches at the tip in the experimental versus control 
lung. (C) FACS for EpCAM+, T1+ and SFTPC+ cells in control and experimental 
lungs at E18.5. Note that the epithelial-mesenchymal ratio of experimental and 
control lungs are similar in spite of reduced size for the mutant. The number of 
SFTPC+ and T1+ cells (over EpCAM+ cells) in experimental versus control lungs 
is significantly reduced. 
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Next, we attenuated FGFR2b signaling from E16.5 to E18.5 (Figure 15A). At E18.5 
the experimental (n=5) and control (n=3) lungs were macroscopically 
undistinguishable (Figure 15B). The proportions of EpCAM-positive, T1-positive 
and SFTPC-positive cells were quantified by FACS. No changes were observed for 
the EpCAM ratio between experimental and control lungs (as well as for the total 
number of EpCAM-positive cells - data not shown). Interestingly, we found a 
reduction in the ratio of AECII cells associated with an increase in the ratio of AECI 
cells which suggests that FGF signaling controls the differentiation balance 
between AECI and AECII in favor of AECII cells (Figure 15C).  
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Figure 15: Transient FGFR2b signaling inhibition from E16.5 to E18.5 leads to 
increased T1+ and reduced SFTPC+ cells (over EpCAM+ cells).  
(A) Experimental approach. Pregnant females carrying control and experimental 
embryos were given doxycycline intraperitoneally and via food from E16.5 to 
E18.5. (B) Appearance of the control and experimental lungs at E18.5. 
Macroscopically there was no difference between the experimental versus control 
lung. (C) FACS for EpCAM+, T1+ and SFTPC+ in control and experimental lungs 
at E18.5. Note the reduction in the fraction of AECII cells (SFTPC+) while the 
fraction of AECI (T1+) cells increases. 
 
4.5.2.  Postnatal attenuation of FGFR2b ligands in NOX, during the 
saccular/alveolar stage of lung development, does not cause lung 
structural defects or lethality 
As no congenital mutation in the FGF10 gene in patients with BPD has been 
reported so far, it is reasonable to assume that FGF10 deficiency in BPD patients 
occurs after the premature birth of these babies. It is therefore likely that in BPD 
babies, the initial stages of lung development occur in the presence of normal 
levels of FGF10. To mimic this situation in a mouse model, we again used the 
previously mentioned Rosa26rtTA/+;Tg(tet(O)sFgfr2b)/+ mice. Using this 
approach, we silenced FGFR2b signaling in the postnatal lung during the saccular 
and the beginning of the alveolar stages, between P0 and P8 (Figure 16A-D). In 
NOX, we observed no lethality (Figure 16B) and no structural defects (Figure 
16C,D) between double transgenic experimental lungs (DTG) and single 
transgenic control lungs (STG). Similar results were observed upon exposure to 
doxycycline for a longer time period, from P0 to P105 (Figure S6). 
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Figure 16. Attenuation of FGFR2b ligands postnatally in the context of NOX 
does not affect lung morphology.  
(A) Experimental set-up for NOX of R26rtTA/+;Tg(tet(O)sFgfr2b)/+ (experimental 
group) and R26rtTA/+; +/+ (control group) animals. Animals are fed with 
doxycycline-containing food to induce the dominant negative soluble Fgfr2b in the 
experimental group. (B) Survival curve for NOX exposed animals indicating that all 
experimental and control animals survive in NOX. (C) Haematoxylin/eosin staining 
of NOX exposed (a,b) control or (c,d) experimental lungs at P3. (D) Corresponding 
lung morphometric analysis. Note the absence of differences in (a) MLI, (b) 
airspace and (c) septal wall thickness. Scale bar for Ca,c: 500 µm and Cb,d: 50 
µm. 
 
4.5.3.  Postnatal attenuation of FGFR2b ligands in HOX, during the 
saccular/alveolar stage of lung development, leads to significant lethality due 
to decreased SFTPC expression 
In contrast to NOX, the exposure to HOX induced 50% lethality in the 
Rosa26rtTA/+;Tg(tet(O)sFgfr2b)/+ DTG experimental group, beginning at P6 
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(Figure 17A,B). Compared to Fgf10+/- neonatal mice, this lethality started one day 
later (see Figure 8E) and the lethality rate at P8 was lower (100% versus 50% 
death in Fgf10+/- versus DTG, respectively). Morphometry at P3 (Figure 17C,Da) 
showed increased MLI (+19.3%, p=0.029) between DTG experimental and STG 
control groups. This value, compared to the Fgf10+/- versus WT in HOX (Figure 
8Ga) (+68.2%, p=0.001), supports our conclusion that, in HOX, DTG lungs exhibit 
a less severe phenotype than Fgf10+/- lungs. Overall, we conclude that in HOX a 
complete attenuation of FGFR2b ligands postnatally leads to lethality. However, 
the constitutive decrease in Fgf10 expression throughout the different phases of 
lung development adds further complications, making the phenotype more severe.  
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Figure 17. Attenuation of FGFR2b ligands postnatally in the context of HOX 
exposed pups leads to significant lethality.  
(A) Experimental set-up for HOX of R26rtTA/+;Tg(tet(O)sFgfr2b)/+ (experimental 
group) and R26rtTA/+; +/+ (control group) animals. (B) Survival curve for HOX 
exposed animals indicating that 50% of the experimental animals die within 8 days 
while all the control animals survive. (C) Haematoxylin/eosin staining of HOX 
exposed (a,b) control or (c,d) experimental lungs at P3. (D) Corresponding lung 
morphometric analysis of HOX exposed control and experimental animals. Note 
the increase in (a) MLI while (b) airspace and (c) septal wall thickness are not 
affected. Scale bar for Ca,c: 500 µm and Cb,d: 50 µm. 
 
As the Fgf10+/- versus WT lungs at P3 in HOX presented quantitative defects 
(increased AECI, decreased AECII) as well as impaired AECII differentiation 
(reduced AECII signature, increased AECI signature) associated with reduced 
SFTPC expression, we also carried out western blot for SFTPC and FACS analysis 
to quantify the number of total epithelial cells (using EpCAM as a general marker), 
AECI (T1-positive) and AECII (SFTPC-positive) in DTG and STG P3 lungs in 
NOX and HOX (Figure 18). In NOX, we did not find any significant difference 
between DTG and STG lungs (Figure 18A,B). By contrast, in HOX we observed a 
reduction in SFTPC expression (Figure 18C), suggesting defective AECII cells 
(western blots were done by Negah Ahmadvand). However, FACS analysis failed 
to show quantitative differences between DTG experimental and STG control 
groups for epithelial, AECI and AECII cell numbers (Figure 18D).  
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Figure 18. Rosa26rtTA/+;Tg(tet(o)sFgfr2b)/+ (DTG) lungs in the context of 
HOX exhibit decreased SFTPC expression without quantitative change in the 
prevalence of epithelial (EpCAM+), AECI and AECII cells.  
(A) Western blot analysis for pro-SFTPC and -ACTIN of STG and DTG P3 lungs 
exposed to NOX. Quantification of the western blot results shows no difference 
between STG and DTG mice. (B) Fluorescence Activated Cell Sorting of cells from 
STG and DTG P3 lungs in NOX for Epcam, AECI and AECII cells. No quantitative 
changes are observed in NOX. (C) Western blot analysis for pro-SFTPC and -
ACTIN on STG and DTG P3 lungs exposed to HOX. Quantification of the western 
blot results shows a significant decrease in SFTPC expression in DTG versus STG 
mice. (D) Fluorescence Activated Cell Sorting of cells of STG and DTG P3 lungs in 
HOX for epithelial (EpCAM+), AECI and AECII cells. No quantitative changes are 
observed in HOX. 
 
4.6. Summary of results 
In summary, the questions asked at the beginning of this study (see section 2. 
Objectives) could be answered as follow: 
 
1) Does constitutive Fgf10 deficiency affect embryonic lung development?  
Yes, constitutive Fgf10 deficiency leads to delayed branching of the 
embryonic lung due to decreased proliferation of the epithelium at E12.5. 
Furthermore, at E18.5 the lung morphology and gene expression are 
changed.  
2) What is the impact of constitutive Fgf10 deficiency on the cellular and 
molecular level of the lung? 
On the cellular level constitutive Fgf10 deficiency leads to increase of the 
AECI population on the expense of the AECII population in normoxia and 
hyperoxia. Genes for FGF10 signaling was downregulated and genes for 
TGF- signaling was upregulated at E18.5. Most important, in isolated 
AECII cells the gene signatures for AECII is decreased. Instead, the AECII 
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cells acquire the gene signatures of AECI cells. 
3) What is the impact of constitutive Fgf10 deficiency on hyperoxia lung injury 
in the newborn (BPD mouse model)? 
Constitutive Fgf10 deficiency leads to quantitative and qualitative defects of 
the AECII cells resulting in susceptibility of the lung towards oxygen toxicity 
(BPD mouse model). As a consequence of this susceptibility the lung 
epithelium reveals a higher degree of damage and significant decrease in 
surfactant protein B and C production upon hyperoxia lung injury, which 
leads to death.  
4) Does blockade of FGF10/FGFR2b signaling affect embryonic and postnatal 
lung development? 
Yes, blockade of FGF10/FGFR2b signaling starting at late pseudoglandular 
stage (E14.5) leads to decrease of AECI and AECII. In comparison, 
blockade of FGF10/FGFR2b signaling starting at saccular stage (E16.5) 
reveals a quantitative increase of AECI on the expenses of AECII. In 
contrast, postnatal blockade of FGF10/FGFR2b signaling from P0-P105 
does not affect lung structure.  
5) Is FGF10/FGFR2b signaling relevant during postnatal hyperoxia lung injury? 
FGF10/FGFR2b signaling during postnatal hyperoxia lung injury is relevant 
since a blockade leads to lethality due to increased damage of the lung 
tissue and decreased production of surfactant protein C. 
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5.   Discussion  
Our study provides, for the first time, experimental evidence in mice that Fgf10-
mRNA levels are critical for proper alveolar lineage formation. Fgf10 is essential for 
the proper differentiation of the AECII cells and for the formation of the appropriate 
number and ratio of AECII versus AECI cells. In the presence of reduced Fgf10 
expression, the differentiation of AECII cells is impaired, as evidenced by the 
reduced expression of AECII markers and the concomitant increased expression of 
AECI markers. Furthermore, FACS analysis indicates that, compared to their WT 
littermates, the ratio of AECI cells to the total number of EpCAM-positive cells is 
increased, while that of AECII cells ratio is decreased. In the context of HOX injury, 
these quantitative and qualitative defects in the alveolar lineage are associated 
with 100% lethality, which most likely results from the observed defective 
surfactant production. This supports our conclusion that defective AECII cells are 
causative for this lethal phenotype. Interestingly, decrease in FGF10 expression 
has also been reported in the lungs of BPD patients. Premature babies at risk of 
developing BPD are generally born between 24 and 28 weeks, which corresponds 
to the end of the canalicular/mid-saccular stages of lung development. This is the 
time when the bipotent epithelial progenitors in the alveolar lineage differentiate 
into AECI and AECII. Supporting the observation of AECII defects in BPD patients, 
a collaborative project provided evidence for decreased SFTPC expression in 
lungs of patients with BPD by using immunostaining (data not shown). We also 
have demonstrated that the attenuation of FGFR2b signaling during the saccular 
stage, in the context of HOX injury, leads to lethality due to abnormal surfactant 
production. Altogether, our results demonstrate a critical role for Fgf10 in alveolar 
lineage formation and suggest that quantitative and qualitative differences in AECII 
could be causative for lethality in BPD patients. 
5.1.  Take home message on the transcriptional approach 
An unbiased transcriptional approach was carried out with isolated AECII cells from 
Fgf10+/- and WT P3 lungs in HOX and NOX. Overall, at this time point, focusing on 
a specific cellular target of FGF10 signaling, our approach failed to find major 
differences between the two genotypes that could explain the lethal phenotype. 
Most of the differences identified in the analysis "hyperoxia x genotype" revealed 
changes in KEGG pathways dealing with the immune response, such as 
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staphylococcus aureus infection, antigen processing and presentation, and graft 
versus host disease. Since the lung epithelium is the first line of defense to 
bacterial or viral infections, in the future it will be important to define how Fgf10 
controls inflammation via its action on AECII cells. Interestingly, inflammation has 
been shown to inhibit Fgf10 expression (Benjamin et al., 2010). FGF10 also 
prevents LPS-induced acute lung injury in rats (Tong et al., 2014). A first hint that 
the AECII cells in Fgf10+/- versus WT were defective was obtained by the analysis 
of AECII differentiation using the previously described AECII and AECI signatures 
(Treutlein et al., 2014). This is the first time, to our knowledge, that these specific 
alveolar epithelial signatures have been validated in disease lung models and it 
underscores the importance of a better definition, at the molecular level, of the 
AECII cells. 
5.2.  Fgf10 controls the differentiation of the epithelium along the 
alveolar/AECII lineage 
Fgf10 has been previously described to maintain the undifferentiated status of the 
SOX9/ID2 positive cells in the distal epithelium (Volckaert et al., 2013; Nyeng et al., 
2008). These are considered to be mutipotent epithelial progenitor cells in the 
developing lung. Lineage tracing using Id2-CreERT2 showed that they give rise to 
both bronchiolar and alveolar progenitors. Based on single cell transcriptome 
studies of the developing epithelium, the alveolar progenitors have been proposed 
to represent a population of “bipotent progenitor cells”. These bipotent cells can 
differentiate into either AECI or AECII cells. However, what controls their 
differentiation remains unknown. A gene signature characteristic of each cell type 
has been described. The bipotent progenitor cells exhibit both signatures. Our 
results suggest that Fgf10 may play a key role in directing the differentiation of the 
bipotent progenitor cells towards the AECII lineage (Figure 19). This conclusion is 
based on the observation that while the total number of epithelial cells is decreased 
in Fgf10+/- lungs, the ratio of AECII cells (to the total number of EpCAM-positive 
cells) is also decreased, while that of AECI cells is increased. Interestingly, Fgf10 
hypomorphic lungs, exhibiting around 20% of the WT Fgf10 mRNA level, also 
show a pronounced defect in AECII cells (Ramasamy et al., 2007), supporting a 
role for Fgf10 in the ontogeny of the AECII lineage. In the future, lineage-tracing 
studies of the bipotent progenitor cells in the context of Fgf10 deficiency should be 
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performed to test this hypothesis. If this is a consequence of direct FGF10 
signaling to the epithelium via FGFR2b, then the specific deletion of Fgfr2b in 
these bipotent progenitor cells should only allow the formation of AECI cells. The 
role of the other FGFR2b ligands in this differentiation process, which are 
abundantly expressed in the lung (mainly FGF1 and FGF7), is unclear and will also 
need to be addressed. The observation that surfactant production, which is AECII’s 
primary function, is compromised in Fgf10+/- in HOX supports our conclusion that 
AECII cells from Fgf10+/- lungs are deficient. Interestingly, AECII cells in Fgf10+/- 
lungs are still capable of producing adequate surfactant to allow normal lung 
function in room air. However, following HOX, it seems that these cells are 
prematurely lost due to built in developmental (differentiation) defects that remain 
to be defined. These defects assumably lead to either more susceptibility of AECII 
to HOX injury or decrease in regenerative capacity of AECII stem cells 
(Barkauskas et al., 2013) or other still unidentified sources. In WT mice, AECII cells 
are also affected by HOX. Figure 12Bc,g indicates a 19% drop in HOX versus 
NOX. Interestingly, the AECII cells in Fgf10+/- drop less (8% decrease in HOX 
versus NOX), indicating that AECII cells in Fgf10+/- lungs attempt to replenish the 
failing AECII pool. In this regard, another project in our laboratory found an 
increase in epithelial proliferation by using immunostaining. Confirming the FACS 
results, the western blot analysis clearly shows a significant decrease in SFTPC 
production, which is likely a major contributor to the lethal phenotype upon injury. 
Interestingly, the genome-wide association study failed to associate single-
nucleotide polymorphisms in the FGF10 gene with BPD. Constitutive mutations in 
FGF10 therefore appear to be rare, or non-existent, in BPD patients. However, the 
reduction in FGF10, which is linked to inflammation, is likely directly associated 
with the clinical manifestations. It is noteworthy that BPD occurs in the context of 
lung immaturity superimposed by iatrogenic injury. The more immature the infant’s 
lung is, the higher is the risk for developmental defects that may interfere with 
normal repair of injuries. Our results are also of concern regarding ALSG or LADD 
patients (exhibiting FGF10 or FGFR2b mutations). While these patients initially 
appear to have normal function, they develop chronic obstructive pulmonary 
disease (Klar et al., 2011). This is likely associated with deficient repair of the 
epithelium upon injury. It still remains to be investigated whether this is due to 
developmental defects in the epithelial progenitors and/or insufficient postnatal 
Fgf10 levels that compromise epithelial maintenance. One aspect is clear; these 
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patients will likely be more prone to lung disease than the normal population. At a 
minimum, preventive measures should be considered for these “at risk” patients.  
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Figure 19. Model for the role of Fgf10 in alveolar lineage formation during 
embryonic lung development. 
We hypothesize that Fgf10, among others, is controlling the differentiation of the 
multipotent progenitor cells (ID2+, SOX9+) located at the distal tip of the branches 
towards the alveolar progenitor cells (ID2+, SOX9+) during the pseudoglandular 
stage of embryonic lung development. In turn, the alveolar progenitor cells will give 
rise to the bipotent progenitor cells during the saccular stage which display both 
AECI and AECII gene signatures. Whether the bipotent progenitor cells could arise 
directly from the multipotent progenitor cells needs to be proven. Our data suggest 
that Fgf10 might orchestrate the differentiation as well as the survival/proliferation 
of this progenitor cell population. Finally, our data give evidence that Fgf10  
promotes the differentiation of the bipotent progenitor cell towards the AECII cell 
(modified from El Agha et al., 2014).  
 
5.3.  Impact of Fgf10 deficiency on the vascular system 
We have previously reported a clear link between Fgf10 deficiency and vascular 
defects in Fgf10Lacz/- hypomorphic lungs (Ramasamy et al., 2007). We showed that 
Vegfa is a target of FGF10 in the developing lung epithelium and that decreased 
Fgf10 levels eventually translate into decreased Vegfa and associated vascular 
defects. Another project from our group dealing with the effect of Fgf10 deficiency 
on the development of the pulmonary vasculature found that Vegfa shows a trend 
towards reduction in E18.5 Fgf10+/- lungs. In the Fgf10Lacz/- hypomorphic lungs, the 
vascular tree is severely underdeveloped (Ramasamy et al., 2007). Such defects 
were not observed in P3 Fgf10+/- lungs in NOX, but emerge after HOX exposure, 
and are characterized by a significant drop in the number of blood vessels and by 
more immature (smooth muscle actin-negative) blood vessels (Figure 13). 
However, these defects did not seem to lead to lung hemorrhages, either at P3 or 
at later time points analyzed, suggesting that the observed lethality is not due to a 
failing vascular system. Interestingly, vascular defects, primarily pulmonary 
hypertension (PH), have been proposed as the main causes of lethality in infants 
with BPD (Kool et al., 2014). The PH phenotype was not observed in our 
experimental model, which suggests that additional pathways affecting the 
vascular system are implicated in BPD. However, the presence of more immature 
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(smooth muscle actin-negative) blood vessels in our experimental model raises the 
possibility that FGF10 signaling contributes to the formation of vascular smooth 
muscle cells via its action on PDGFB (Ramasamy et al., 2007), or via a more direct 
action on smooth muscle cell progenitors. Interestingly, FGF10 has been shown to 
act directly on mesenchymal-derived cells such as cardiomyocytes (Rochais et al., 
2014), adipocyte stem cells (Sakaue et al., 2002), and lipofibroblasts (Al Alam et 
al., 2015), supporting the idea that in the lung FGF10 does not only act on the 
epithelium. In addition to its role on the epithelium and mesenchyme, it was also 
recently reported that FGF signaling to the endothelial cells is required for injury 
response, but not for vascular homeostasis (Oladipupo et al., 2014). FGF10 has 
also been shown to directly support the proliferation of endothelial cells (Sugimoto 
et al., 2014). It is therefore tempting to subdivide the effects of decreased Fgf10 
expression on the vasculature into two classes: one class linked to developmental 
defects where the blood vessels are more sensitive and immature, and one class 
linked to the role of FGF10 in repair as a proliferative factor for the endothelium, 
thereby limiting the vascular damages triggered by HOX. In Fgf10+/- mice, the 
normal function of the vasculature is likely affected by both developmental defects 
and insufficient repair upon injury. 
5.4.  Role of FGF10 signaling in secondary septa formation during 
alveologenesis 
Alveologenesis is critical to the formation of the alveoli from lung saccules. Alveoli 
represent the minimal respiratory unit of the lung. Their formation is initiated by 
emergence of the secondary septa, a transient elongated structure emerging from 
the saccular walls. Secondary septa are composed of alveolar myofibroblasts, 
which deposit elastin at their apex. Both elastin and alveolar myofibroblasts are 
critical for the formation of the secondary septa as demonstrated by the elastin Ko 
mice (Wendel et al., 2000) and Pdgfa ko mice (Bostrom et al., 1996) in both of 
which alveologenesis is significantly reduced or blocked. The origin of the alveolar 
myofibroblasts is still controversial. However, it appears that FGFR2b ligands are 
critical for their formation. Fgf10Lacz/- hypomorphic lungs (expressing only 20% of 
WT) display enlarged respiratory airways at birth, characterized by the absence of 
smooth muscle actin myofibroblasts (Ramasamy et al., 2007).  
Consistent with a role for FGF10 signaling in the formation of the alveolar 
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myofibroblasts, the inhibition of FGFR2b ligands using the soluble Fgfr2b approach 
from E16.5 to E18.5 leads to impaired postnatal alveologenesis (Hokuto et al., 
2003). In this context, defective secondary septa formation can be corrected by 
retinoic acid. However, re-expression of the dominant negative soluble Fgfr2b also 
blocks the regeneration process, indicating that FGFR2b ligands expressed in the 
postnatal lung are also critical for the formation of the secondary septa (Perl & 
Gale, 2009). Secondary septa formation can also be induced following left lung 
pneumonectomy in mice. The formation of the new secondary septa is inhibited by 
the expression of the dominant negative soluble Fgfr2b (Chen et al., 2012). These 
data indicate that one or several FGFR2b ligands, in particular FGF10, are directly 
responsible for the formation of the alveolar myofibroblasts. However, it is still 
unclear if this is a direct effect of FGF10 on the alveolar myofibroblast progenitors 
or an indirect effect via FGF10 action on AECII cells, which are also a major 
component of the forming alveoli. Use of specific driver lines to target the alveolar 
myofibroblast progenitors will be instrumental to follow their fates in the context of 
lung injury or regeneration.  
5.5.  Future perspectives  
In view of the numerous lung diseases characterized by lack and/or destruction of 
alveoli (e.g. BPD, COPD), the fundamental understanding of the alveologenesis 
process with its coordinated cellular interactions and intricate signaling network 
which exists between epithelial, mesenchymal and endothelial is essential. For this 
purpose, developmental biologists have been working extensively to unravel the 
molecular and cellular bases of mouse lung development, both pre- and 
postnatally. In this context, Fgf10 has been shown to be a major player for the 
processes in development and repair after lung injury. In the future, the 
pneumonectomy mouse model combined with genetically modified mouse lines, 
lineage tracing approaches and single cell transcriptomic analyses will be powerful 
tools to shed new lights on the regenerative aspects associated with de novo 
alveologenesis. Last, but not least, the knowledge about progenitor / stem cells 
located in niches of the postnatal lung will be a valuable source of information that 
would be useful in triggering lung regeneration subsequent to injury. Such 
knowledge is critical to develop innovative therapies to treat lung diseases. 
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6.   Summary  
The evidence confirming the key role of Fgf10 in embryonic lung development is 
strong. Inflammation-induced FGF10 deficiency has been shown in preterm infants 
who suffer from bronchopulmonary dysplasia (BPD) but only little is known about 
the underlying mechanism. Thus, information regarding the role of this major 
signaling pathway may open new therapeutic avenues to protect or regenerate the 
alveolar structure in particular. To demonstrate the effect of Fgf10 deficiency for 
prenatal and postnatal lung development in normoxic conditions, we used a 
constitutive heterozygous Fgf10+/- mouse line. Lung morphometry and gene array 
were performed to identify changes in lung structure and global gene expression in 
Fgf10+/- versus Fgf10+/+ (WT) littermate lungs at E18.5. As oxygen toxicity is one of 
the major risk factors contributing to BPD we used the hyperoxia-induced BPD 
mouse model (85% oxygen from P0 – P8) to investigate the impact of Fgf10 
deficiency. Surprisingly, 100% of Fgf10+/- pups died within 8 days of hyperoxia 
injury. We therefore chose P3, a time point at which there was no observable 
lethality, to collect pups for further analysis involving lung morphometry, gene 
array, fluorescence activated cell sorting (FACS), immunofluorescence (IF), 
reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), and 
western blot. In summary, constitutive decrease in Fgf10 mRNA levels leads to 
lung congenital defects, which are compatible with postnatal survival, but which 
compromise the ability of the lungs to cope with sub-lethal hyperoxia injury. The 
results provide evidence that Fgf10 deficiency during embryonic lung development 
affects the formation of AECII quantitatively and qualitatively. Considering that the 
vascular compartment of the lung plays a pivotal role in the control of lung 
epithelial growth (Thebaud, 2007; Thebaud & Abman, 2007), we also used 
vascular morphometry (vessel count and vessel muscularization) to determine 
potential pathological changes. Furthermore, we used a previously described 
double transgenic system in mice to attenuate all FGFR2b ligands pre- and post-
natally in the context of hyperoxia injury (Danopoulos et al., 2013; MacKenzie et 
al., 2015; Parsa et al., 2010; Parsa et al., 2008; Al Alam et al., 2015).  
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Summary of results: 
During lung development, our findings demonstrate that: 
1. Neonatal Fgf10 expression in the wild type lung is low in normoxia and 
decrease significantly upon hyperoxia. 
2. Fgf10+/- mice at E12.5 show significant decrease in Fgf10 expression and 
delayed branching morphogenesis due to decreased proliferation of the 
epithelium. 
3. Fgf10+/- mice show impaired lung morphology and differential gene 
expression at E18.5. 
4. Fgf10+/- mice at P70 reveal impaired lung morphology and lung function.  
5. Blood vessel numbers and their muscularization are indistinguishable 
between Fgf10+/- versus WT lungs. 
 
In the context of neonatal hyperoxia lung injury our results show that: 
1. Fgf10+/- mice reveal 100% lethality and significant defects in lung 
morphology. 
2. Fgf10+/- mice show quantitative and qualitative defects of AEC II cells. 
3. Fgf10+/- mice show decreased number of blood vessels and decreased 
muscularization. 
 
In the context of attenuation of FGFR2b ligands we observed that: 
1. Prenatal attenuation affects the formation of the AECI and AECII 
quantitatively. 
2. In normoxia postnatal attenuation during the saccular/alveolar stage of lung 
development does not cause lung structural defects or lethality. 
3. In hyperoxia postnatal attenuation during the saccular/alveolar stage of lung 
development leads to significant lethality due to decreased surfactant 
protein C (SFTPC) expression. 
We report for the first time the precise and detailed analysis of the consequence of 
Fgf10 deficiency in mice on normal lung development and during hyperoxia injury. 
Our results indicate that FGF10 deficiency in neonates with BPD could be linked to 
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defective alveolar epithelial lineage formation. In turn, deficient AECII cells could 
be causative for some of the observed lung defects. This knowledge may be critical 
in designing therapies to prevent lung injury in neonates at risk for BPD and in lung 
disorders characterized by Fgf10 deficiency. 
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7.   Zusammenfassung  
Die Schlüsselrolle von Fgf10 für die embryonale Lungenentwicklung ist hinreichend 
belegt. Bei Frühgeborenen mit Bronchopulmonale Dysplasie (BPD) konnte eine 
durch Inflammation induzierte verminderte Expression von FGF10 gezeigt werden. 
Der zugrundeliegende Mechanismus ist jedoch kaum bekannt. Daher würde das 
tiefere Verständnis hinsichtlich der Rolle dieses essentiellen Signalweges in der 
Protektion und Regeneration der Alveolen möglicherweise neue therapeutische 
Wege eröffnen. Um den Effekt von Fgf10 Defizienz auf die prä- und postnatale 
Lungenentwicklung zu untersuchen, griffen wir auf eine Fgf10+/- Mauslinie zurück, 
die heterozygot für Fgf10 ist. Mit Hilfe der Lungenmorphometrie und Gene Array 
Analysen wurden Veränderungen in der Lungenstruktur und der globalen 
Genexpression an E18.5 bei Fgf10+/- versus Fgf10+/+ (Wildtyp) Geschwistertieren 
erfasst. Da die Sauerstofftoxizität eine der Hauptfaktoren in der Pathogenese der 
BPD ist, wurden die Auswirkungen der Fgf10 Defizienz in einem durch Hyperoxie 
induzierten BPD Mausmodell (85% O2 von P0-P8) untersucht. Es konnte 
festgestellt werden, dass 100% der Fgf10+/- Mäuse während der Hyperoxiephase 
versterben, während alle WT Mäuse überlebten. Weitergehende Untersuchungen 
wurden an P3 mit Hilfe von Lungenmorphometrie, Gene Array, FACS, 
Immunhistochemie/ Immunfluoreszenz, RT-qPCR und Western blot durchgeführt. 
Zusammenfassend kann konstatiert werden, dass eine konstitutive Fgf10 Defizienz 
zu kongenitalen Lungendefekten führt, die zwar postnatal mit dem Überleben 
vereinbar sind, jedoch bei Auftreten einer Hyperoxie-induzierten 
Lungenschädigung zu einer erhöhten Vulnerabilität der Lunge führen. Die erzielten 
Resultate weisen auf quantitative und qualitative Defekte der Alveolarepithelzellen 
Typ II (AECII) hin, welche auf die Fgf10 Defizienz zurückzuführen sind. Da das 
Gefäßkompartiment ebenfalls mit dem Wachstum des Lungenepithels in 
Zusammenhang steht (Thebaud, 2007; Thebaud & Abman, 2007), wurden mittels 
Gefäßmorphometrie (Anzahl der Gefäße und ihre Muskularisierung) potenzielle 
Veränderungen analysiert. Schließlich wurden mit Hilfe einer induzierbaren 
Mauslinie in vivo FGFR2B Liganden prä- und postnatal während der 
Hyperoxiephase blockiert und die Effekte untersucht (Danopoulos et al., 2013; 
MacKenzie et al., 2015; Parsa et al., 2010; Parsa et al., 2008; Al Alam et al., 2015). 
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Zusammenfassung der Resultate: 
Während der Lungenentwicklung lässt sich folgendes feststellen: 
1. In Normoxie ist die neonatale Fgf10 Expression bei Wildtyp Mäusen niedrig, 
während sie in Hyperoxie signifikant abnimmt.  
2. Fgf10+/- Mäuse zeigen an E12.5 eine erniedrigte Fgf10 Expression und eine 
verzögerte Verästelung der Lunge aufgrund einer verminderten Proliferation 
des Epithels. 
3. Fgf10+/- Mäuse zeigen an E18.5 eine veränderte Lungenmorphologie und 
veränderte Genexpression.  
4. Fgf10+/- Mäuse zeigen an P70 eine veränderte Lungenmorphologie und 
verminderte Lungenfunktion.  
5. Fgf10+/- Mäuse zeigen an P3 keine Veränderungen der Gefäße (Anzahl und 
Muskularisierung). 
 
Im Kontext der neonatalen Hyperoxie-induzierten Lungenschädigung ergaben die 
Resultate folgendes: 
1. Fgf10+/- Mäuse zeigen eine 100%-ige Letalität mit einer signifikant 
schwerwiegenderen Lungenschädigung. 
2. Fgf10+/- Mäuse zeigen an P3 quantitative und qualitative Defekte der AECII. 
3. Fgf10+/- Mäuse zeigen an P3 eine verminderte Anzahl und Muskularisierung 
der Gefäße. 
 
Im Zusammenhang mit der Blockade von FGFR2b Liganden beobachteten wir 
folgendes: 
1. Eine pränatale Blockade von FGFR2b Liganden führt zur quantitativen 
Fehldifferenzierung der AECI und AECII. 
2. In Normoxie führt eine postnatale Blockade von FGFR2b Liganden im 
sakkulären/alveolären Stadium der Lungenentwicklung zu keinen Defekten 
der Lungenstruktur und keiner Letalität.  
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3. In Hyperoxie führt eine postnatale Blockade von FGFR2b Liganden im 
sakkulären/alveolären Stadium der Lungenentwicklung zu einer erhöhten 
Letalität assoziiert mit einer verminderten Surfactant protein C (SFTPC) 
Expression. 
Zusammenfasssend berichten wir erstmalig präzise und detailliert über die Effekte 
einer Fgf10 Defizienz auf die normale Lungenentwicklung und die Hyperoxie-
induzierte Lungenschädigung (BPD Mausmodell). Unsere Resultate zeigen, dass 
Fgf10 Defizienz bei Neugeborenen mit BPD mit einer gestörten Bildung der 
Alveolarepithelzellen assoziiert sein könnte. Andererseits könnten defiziente AECII 
ursächlich zu der Pathogenese der BPD beitragen. Die Resultate der vorliegenden 
Arbeit können für zukünftige Therapieansätze zur Behandlung von Patienten mit 
BPD oder Lungenerkrankungen mit Fgf10 Defizienz von Nutzen sein.  
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Figure S1. Identification of sets of genes differentially expressed in HOX 
versus NOX (selected according to their p-values) in isolated AECII cells 
from WT and Fgf10+/-.   
(A) Volcanoplots. (B) Volcanoplot for HOX versus NOX in isolated AECII cells from 
Fgf10+/+ (WT) lungs. (C) Volcanoplot for HOX versus NOX in isolated AECII cells 
from Fgf10+/- lungs. (D) Volcanoplot in isolated AECII cells from Fgf10+/- versus WT 
in NOX. (E) Volcanoplot in isolated AECII cells from Fgf10+/- versus WT in HOX. (F) 
Hyperoxia effect HOX versus NOX. (G) (a) heat map: top 100 regulated genes 
selected based on their p value between NOX and Hox in isolated AECII cells from 
WT lungs. (b) heat map: analysis of the same top 100 genes between NOX and 
HOX in isolated AECII cells from Fgf10+/- lungs. (H) Genotype effect. (I) (a) heat 
map: top 100 regulated genes between isolated AECII cells from Fgf10+/- versus 
WT lungs in NOX. (b) heat map: analysis of the same top 100 genes between 
isolated AECII cells from Fgf10+/- versus WT lungs in HOX. 
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Figure S2. Magnification of the graphs shown in Figure 11Ba,b. 
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Figure S3. Greater magnification of the graphs shown in Figure 11D,E. 
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Figure S4. Fgf10+/- lungs at P70 in the context of NOX exhibit more AECI but 
less AECII.  
(A) Fluorescence Activated Cell Sorting in NOX (a-c) of Fgf10+/+ and Fgf10+/- P70 
lungs for (a) epithelial cells (EpCAM+), (b) AECI and (c) AECII.  
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Figure S5. The impact of HOX versus NOX on the mesenchymal, 
hematopoietic and endothelial cells of Fgf10+/- and WT lungs at P3.  
(A) FACS-based quantification of mesenchymal cells (CD45-;CD31-; EpCAM-) as 
a percentage of total cells in (a) NOX and (b) HOX. (B) FACS-based quantification 
of hematopoietic and endothelial cells (CD45+;CD31+; EpCAM-) as a percentage 
of total cells in (a) NOX and (b) HOX. Fgf10+/- lungs: n=4 and n=5 for HOX versus 
NOX, respectively. WT lungs: n=4 and n=5 for HOX versus NOX, respectively.  
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Figure S6. Attenuation of FGFR2B ligands postnatally from P0-P105 in NOX 
does not lead to changes in lung structure.  
(A) Experimental set-up of R26rtTA/+; +/+ (control group) and R26rtTA/+; 
Tg(tet(O)sFgfr2b)/+ (experimental group) animals. All animals are fed with 
doxycycline-containing food to induce the dominant negative soluble Fgfr2b in the 
experimental group. (B) Haematoxylin/eosin staining of (a) control or (b) 
experimental lungs at P105. (C) Corresponding lung morphometric analysis. Note 
the absence of differences in (a) MLI, (b) airspace and (c) septal wall thickness. 
Scale bar for Ba,b: 500 µm. 
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